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A B S T R A C T
Background
Illicit drug use in pregnancy is a complex social and public health problem. The consequences of drug use in pregnancy are high for both
the woman and her child. Therefore, it is important to develop and evaluate effective treatments. There is evidence for the effectiveness
of psychosocial interventions in drug treatment but it is unclear whether they are effective in pregnant women. This is an update of a
Cochrane review originally published in 2007.
Objectives
To evaluate the effectiveness of psychosocial interventions in pregnant women enrolled in illicit drug treatment programmes on birth
and neonatal outcomes, on attendance and retention in treatment, as well as on maternal and neonatal drug abstinence. In short, do
psychosocial interventions translate into less illicit drug use, greater abstinence, better birth outcomes, or greater clinic attendance?
Search methods
We conducted the original literature search in May 2006 and performed the search update up to January 2015. For both review stages
(original and update), we searched the Cochrane Drugs and Alcohol Group Trial’s register (May 2006 and January 2015); the Cochrane
Central Register of Trials (CENTRAL; the Cochrane Library 2015, Issue 1); PubMed (1996 to January 2015); EMBASE (1996 to
January 2015); and CINAHL (1982 to January 2015).
Selection criteria
We included randomized controlled trials comparing any psychosocial intervention vs. a control intervention that could include
pharmacological treatment, such as methadone maintenance, a different psychosocial intervention, counselling, prenatal care, STD
counselling and testing, transportation, or childcare.
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Data collection and analysis
We used standard methodological procedures expected by the Cochrane Collaboration. We performed analyses based on three com-
parisons: any psychosocial intervention vs. control, contingency management (CM) interventions vs. control, and motivational inter-
viewing based (MIB) interventions vs. control.
Main results
In total, we included 14 studies with 1298 participants: nine studies (704 participants) compared CM vs. control, and five studies (594
participants) comparedMIB interventions vs. control.We did not find any studies that assessed other types of psychosocial interventions.
For the most part, it was unclear if included studies adequately controlled for biases within their studies as such information was not
often reported. We assessed risk of bias in the included studies relating to participant selection, allocation concealment, personnel and
outcome assessor blinding, and attrition.
The included trials rarely captured maternal and neonatal outcomes. For studies that did measure such outcomes, no difference was
observed in pre-term birth rates (RR 0.71, 95% confidence interval (CI) 0.34 to 1.51; three trials, 264 participants, moderate quality
evidence), maternal toxicity at delivery (RR 1.18, 95% CI 0.52 to 2.65; two trials, 217 participants, moderate quality evidence), or low
birth weight (RR 0.72, 95% CI 0.36 to 1.43; one trial, 160 participants, moderate quality evidence). However, the results did show
that neonates remained in hospital for fewer days after delivery in CM intervention groups (RR -1.27, 95% CI -2.52 to -0.03; two
trials, 103 participants, moderate quality evidence). There were no differences observed at the end of studies in retention or abstinence
(as assessed by positive drug test at the end of treatment) in any psychosocial intervention group compared to control (Retention: RR
0.99, 95% CI 0.93 to 1.06, nine trials, 743 participants, low quality evidence; and Abstinence: RR 1.14, 95% CI 0.75 to 1.73, three
trials, 367 participants, low quality evidence). These results held for both CM and MIB combined. Overall, the quality of the evidence
was low to moderate.
Authors’ conclusions
The present evidence suggests that there is no difference in treatment outcomes to address drug use in pregnant women with use of
psychosocial interventions, when taken in the presence of other comprehensive care options. However, few studies evaluated obstetrical
or neonatal outcomes and rarely did so in a systematic way, making it difficult to assess the effect of psychosocial interventions on these
clinically important outcomes. It is important to develop a better evidence base to evaluate psychosocial modalities of treatment in this
important population.
P L A I N L A N G U A G E S U M M A R Y
Psychosocial interventions for pregnantwomen in outpatient illicit drug treatment programmes compared to other interventions
Review question
We reviewed the evidence about the effect of psychosocial interventions, such as contingency management (CM) and motivational
interviewing based (MIB) techniques vs. usual care for pregnant women in outpatient illicit drug treatment programmes.
Background
Women who use illicit drugs while pregnant are more likely to give birth early and have low birthweight infants. A pregnant woman
can reduce the risk of these complications by undergoing drug treatment during pregnancy.
Psychosocial interventions, such asCMandMIB techniques,may help them toovercome themany barriers to staying in a drug treatment
programme and reduce illicit drug use. CM uses positive supportive reinforcement with incentives, such as monetary vouchers, awarded
based on pre-determined endpoints such as treatment attendance or drug abstinence. MIB is a form of patient-centred counselling
used to resolve uncertainty in their drug use, treatment, or cessation.
Study characteristics
Researchers from the Cochrane Collaboration examined the evidence published up to January 2015 and included 14 studies with
1298 pregnant women in this Cochrane review. The 1298 pregnant women received either CM or MIB techniques in adjunct to
other comprehensive care options; women in the control group received usual care that included pharmacological treatment such as
methadone maintenance, counselling, prenatal care, STD counselling and testing, transportation, and/or childcare. Nine studies used
CM techniques vs. usual care, while five studies involved MIB techniques vs. usual care.
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All of the studies were completed in the United States of America and most participants were African American. Most studies used the
Diagnostic and Statistical Manual of Mental Disorders (DSM-IV-R) criteria to determine drug dependence.
Key results
There were no differences in retention or abstinence between CM or MIB techniques and usual care. There were also no differences in
birth outcomes between the groups.
Overall, there is low to moderate quality of evidence from the included studies. Allocation methods were often described in very limited
manner. Furthermore, many studies lacked attrition information which could have impacted results. While further information related
to these methods could be helpful, future randomized trials using psychosocial interventions are unlikely to show a benefit. In addition,
there was significant heterogeneity in terms of methods for measuring outcomes.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Outcomes Relative effect
(95% CI)
No of participants
(studies)
Quality of the evidence
(GRADE)
Patients: Pregnant women enrolled in illicit drug treatment programs for any treatment of substance abuse or dependence of any drug
Settings: Outpatient treatment facilities
Intervention: Psychosocial interventions of any kind (including Contingency Management methods and Motivational Interviewing based
techniques) alone or given in addition to usual care
Comparison: Comprehensive usual care such as methadone maintenance, counselling, prenatal care (PNC), STD counselling and
testing, transportation, and/or childcare
Preterm birth (<37 weeks ges-
tation)
(Any psychosocial intervention
vs. control)
RR 0.71 (95% CI 0.34 to 1.51) 264 (3 studies) ⊕⊕⊕©
moderate 1
Low birth weight (<2500 g)
(Any psychosocial intervention
vs. control)
RR 0.72 (95% CI 0.36 to 1.43) 160 (1 study) ⊕⊕⊕⊕
high
Days hospitalized after delivery
(Any psychosocial intervention
vs. control)
MD -1.27 (95% CI -2.52 to -0.
03)
103 (2 studies) ⊕⊕⊕©
moderate 2
Retention at treatment comple-
tion
(Any psychosocial intervention
vs. control)
RR 0.99 (95% CI 0.93 to 1.06) 743 (9 studies) ⊕⊕©©
low 3
Short term treatment retention
(Any psychosocial intervention
vs. control)
RR 1.00 (95% CI 0.90 to 1.10) 514 (6 studies) ⊕⊕©©
low 4
Positive urine at delivery
(Any psychosocial intervention
vs. control)
RR 1.18 (95% CI 0.52 to 2.65) 217 (2 studies) ⊕⊕⊕⊕
high
Positive urine drug test (end of
treatment)
(Any psychosocial intervention
vs. control)
RR 1.14 (95% CI 0.75 to 1.73) 367 (3 studies) ⊕⊕⊕©
moderate 5
Retention at treatment comple-
tion
(CM vs. control)
RR 1.03 (95% CI 0.92 to 1.16) 388 (6 studies) ⊕⊕©©
low 6
Retention at treatment comple-
tion
(MIB interventions vs. control)
RR 0.97 (95% CI 0.89 to 1.06) 355 (3 studies) ⊕⊕©©
low 7
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CI: Confidence interval; RR: Risk ratio; MD: Mean difference; CM: contingency management; MIB: motivational interviewing based.
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change
the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to
change the estimate.
Very low quality: We are very uncertain about the estimate.
1 Downgraded by one due to possible selection bias in one of the three included studies.
2 Downgraded by one due to possible attrition bias associated with one of the two studies.
3 Downgraded by two due to possible selection bias, attrition bias, and detection bias in majority of the included studies (all but two).
4 Downgraded by two due to possible selection bias, attrition bias, and detection bias in majority of the included studies (all but two).
5 Downgraded by one due to possible selection bias associated with one of the three studies.
6 Downgraded by two due to possible selection bias associated with four of the included studies.
7 Downgraded by two due to possible selection bias associated with two of the included studies.
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx
B A C K G R O U N D
Description of the condition
Illicit drug use among pregnant women is an important and com-
plex public health concern. Since the early 1990s, there has been
a gradual increase in the incidence of illicit drug use in the United
States of America (USA), especially among women of reproductive
age (http://oas.samhsa.gov/women.htm). The most current data
in the USA is from the 2012 National Survey on Drug Use and
Health (http://oas.samhsa.gov/nhsda), in which 5.9% of pregnant
women reported current illicit drug use. Furthermore, the data
showed that 18.3% of pregnant women aged 15 to 17, 9.0% of
women aged 18 to 25, and 3.4% of women aged 26 to 44 were
current users of illicit drugs. A 2010 Australian survey also found
that 4.2% of women who were pregnant, breastfeeding, or both in
the past 12months had used an illicit drug while pregnant (AIHW
2011).
Women who use illicit drugs are more likely to experience adverse
obstetrical andperinatal outcomes thanwomen in the general pop-
ulation (Ludlow 2004). Illicit drug use in pregnancy has been as-
sociated with preterm delivery, low birth weight infants, placental
abruption, neonatal abstinence syndrome (NAS), and Neonatal
Intensive Care Unit (NICU) admission (Sherwood 1999; Ludlow
2004). Cocaine, amphetamines, opioids, and marijuana use has
been linked to premature labour, placental abruption, uterine rup-
ture, fetal distress, neonatal addiction syndrome, and delay in cog-
nitive development (Kuczkowski 2007). There is also conflicting
evidence on long term adverse outcomes, especially among co-
caine exposed infants. Although some studies have shown cog-
nitive deficits at two years of life (Singer 2004), the bulk of the
research points to minimal or absent effects in early childhood, as
summarized well in a systematic review (Frank 2001).
Description of the intervention
Drug treatment interventions can be grouped into either phar-
macological or psychosocial methods. This Cochrane review fo-
cuses only on psychosocial interventions, which involve the use of
contingencymanagement (CM)methods, including vouchers and
other incentives, as well as manual-based techniques such as mo-
tivational interviewing based (MIB) techniques. There are addi-
tional psychosocial interventions including cognitive behavioural
therapy (CBT) and individual psychotherapy. We focused on CM
and MIB techniques because they are the most common.
Contingency management
CM treatments are based on the principle of positive reinforce-
ment as ameans of operant conditioning that influences behaviour
change. It is grounded in the work of Thorndike, especially in
his “Law of Effect”, which states that behavioural responses which
produce a “satisfying” effect are “stamped in” by the experience and
likely to occur more frequently than responses which produce an
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“annoying” effect (Thorndike 1898). This theory was elaborated
by B.F. Skinner who examined the relationship between positive
vs. negative reinforcement and positive vs. negative punishment
in relation to behavioural outcome. Like Thorndike, his research
(initially) involved the use of animals (a pigeon in a box rather
than a cat in a maze). He demonstrated that punishment, regard-
less of whether positive or negative, decreases behaviour whereas
reinforcement increases behaviour, and he attempted to describe
the psycho-dynamic mechanism by which this behaviour change
was affected (Skinner 1947). The premise behind CM is to sys-
tematically use reinforcement techniques to modify behaviour in
a positive and supportive manner. It has been used in the treat-
ment of substance abuse since the 1970s (for a good review see
Sitzer 2006). The most common form of CM has been the use
of monetary vouchers, although prize reinforcers have also been
used. CM was first demonstrated to be efficacious in both treat-
ment retention and substance abstinence in cocaine-dependent
individuals (Higgins 1991), but has subsequently been studied in
opioids, marijuana, cigarettes, alcohol, benzodiazepines, and mul-
tiple drugs. Recently it has been used in populations of pregnant
illicit drug-dependent women.
Motivational interviewing based
MIB techniques are cognitive-behavioural interventions that are
standardized and reproducible. They are based on motivational
interviewing, a concept initially developed for the treatment of
problem drinkers (Miller 2003). It is a directive, client-centred
counselling style for eliciting behaviour change by helping clients
explore and resolve the ambivalence surrounding their substance
use (Rollnick 1995). It draws from the trans-theoretical model of
change (DiClemente 1998) in order to improve treatment readi-
ness and retention. The four included trials each employed a rel-
atively brief MIB intervention. In Mullins 2004, participants in
the intervention group received three one-hour MIB sessions. In
O’Neill 1996, the participants received a total of six sessions last-
ing 60 to 90 minutes each. The first session was MIB, whereas
the subsequent sessions addressed strategies for avoiding high risk
behaviours, including relaxation techniques and problem-solving
techniques. In Haug 2004, the most standardized form of MIB
was employed: motivational enhancement therapy (MET). This
involved four sessions each tailored to the person’s stage of change.
Winhusen 2008 employed three sessions, the first of which em-
phasized rapport building, reflective listening, and affirmation.
The second session focused on providing feedback to the patient
and a discussion of the benefits and consequences of substance
use and pregnancy. The final session centred on either planning
for behaviour change or strengthening commitment to behaviour
change.
How the intervention might work
Drug treatment in pregnancy has been shown to reduce the ma-
ternal and fetal complications associated with illicit drug use
(Kukko 1999; Armstrong 2003). Pregnancy can be considered as a
“window of opportunity” for drug treatment intervention (Daley
1998). Maternal concern for the pregnancy has been thought of
as a motivator to seek drug treatment. Although qualitative stud-
ies have documented maternal motivation (Murphy 1999; Dakof
2003), they have also described themany structural and social bar-
riers to both receiving and remaining in treatment (Boyd 1999;
Murphy 1999). To date, empirical research has failed to demon-
strate better adherence rates to treatment among pregnant women
compared with other people in drug treatment (Hser 1998). In
fact, pregnant women may have higher dropout rates (Howell
2000). Since length of time in treatment is related to positive
outcomes (Grella 2000; Howell 2000), it is important to iden-
tify modalities of treatment retention that are successful in this
specific population. Psychosocial interventions can increase indi-
vidual motivation to remain in treatment and decrease drug use
through the use of incentives, or therapeutic techniques, or both
(Amato 2011a; Amato 2011b)
Why it is important to do this review
The consequences of drug use in pregnancy are great for both
the woman and her child (Ludlow 2004). Psychosocial interven-
tions are widely used in drug treatment but it is unclear whether
or not they work in pregnant women. As no other systematic re-
views have been done on this subject since the first version of this
Cochrane review (Terplan 2007), this update provides a valuable
re-evaluation of the effect of such interventions in this important
population.
O B J E C T I V E S
To assess the effectiveness of psychosocial interventions for women
enrolled in outpatient illicit drug treatment and to evaluate the
effect of such interventions on increasing maternal and neonatal
abstinence, and/or improving attendance and retention.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomized controlled trials (RCTs).
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Types of participants
Pregnant women enrolled in illicit drug treatment programmes
for any treatment of substance abuse or dependence of any drug.
Illicit drugs include illegal substances such as cannabis, heroin,
cocaine, amphetamines, etc. We also included women on metha-
done treatment.
Types of interventions
Experimental
Psychosocial interventions of any kind alone or given in addition
to usual care.
Control
• Comprehensive usual care that included pharmacological
treatment such as methadone maintenance, counselling, prenatal
care (PNC), STD counselling and testing, transportation, and/or
childcare;
• A different psychosocial intervention;
• No intervention.
Types of outcome measures
Primary outcomes
1. Neonatal outcomes:
• Preterm birth (gestational age at birth < 37 weeks);
• -Neonatal toxicology at delivery;
• Low birth weight (birth weight < 2500 g);
• Length of time spent in hospital post delivery.
2. Maternal drug use measured by:
• Maternal toxicology;
• Maternal self-reported drug use.
3. Adverse events for the mother of the child.
Secondary outcomes
4. Retention in treatmentmeasured as number of subjects retained
at the end of the study; or
5. Short term retention in treatment measured as number of sub-
jects retained at the end of one month after enrolment in the study
or greater but before study completion.
Search methods for identification of studies
Electronic searches
We have listed the search methods we used in the original version
of this Cochrane review (Terplan 2007) in Appendix 1.
For the update performed up to 28 January 2015, we searched the
following databases:
• Cochrane Drugs and Alcohol Group Specialized Register
(searched January 2015);
• Cochrane Central Register of Controlled Trials
(CENTRAL) (Cochrane Library 2015, Issue 1) (Appendix 2);
• PubMed (August 2006 to January 2015) (Appendix 3);
• EMBASE (August 2006 to January 2015) (Appendix 4);
• CINAHL (August 2006 to January 2015) (Appendix 5).
We combined the PubMed search with the Cochrane highly sen-
sitive search strategy for identifying randomized trials in MED-
LINE: sensitivity-maximizing version; PubMed format (2008 re-
vision) (Lefebvre 2011).
In addition, we searched for ongoing clinical trials and unpub-
lished studies via internet searches on the following sites:
• ClinicalTrials.gov: www.clinicaltrials.gov (search date: 28
January 2015);
• World Health Organization (WHO) International Clinical
Trials Registry Platform (ICTRP) www.who.int/ictrp/en/ (search
date: 10 January 2015).
Searching other resources
We reviewed the reference lists of all articles obtained as full re-
ports to identify any further studies not retrieved by our elec-
tronic searches. We sought personal communication, conference
abstracts, and unpublished trials from books chapters on treat-
ment of opioid dependence. In addition, we checked the database
of Selective Dissemination (SDI) and the National Institute on
Health (NIH), Bethesda, USA to identify additional studies. We
scanned internet websites, including the National Institute on
Drug Abuse (USA), National Institute on Alcohol Abuse and Al-
coholism (USA) and National Treatment Agency for Substance
Misuse (UK).
We identified trials by handsearching a wide range of healthcare/
addiction journals, including those not indexed in the main elec-
tronic databases and those published in non-English languages.
We did not apply any language restrictions to this Cochrane re-
view.
Data collection and analysis
Selection of studies
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All review authors independently assessed studies for inclusion.
We resolved any conflicts by consensus.
Data extraction and management
All review authors independently extracted data.We discussed any
disagreements and resolved them by consensus. We sought infor-
mation from studies including: participant demographics, what
and when interventions were performed, how and when drug
screening was performed, screening results, measures of retention
and abstinence, and prenatal and maternal outcomes (gestation
length, birth weight, maternal and neonatal toxicity, and neonatal
hospital stay length).
Assessment of risk of bias in included studies
We performed the ’Risk of bias’ assessment for included RCTs and
CCTs using the criteria recommended by the Cochrane Handbook
for Systematic Reviews of Interventions (Higgins 2011). The ’Risk of
bias’ tool for assessing risk of bias in included studies is a two-part
tool, addressing seven specific domains, namely: sequence genera-
tion and allocation concealment (selection bias), blinding of par-
ticipants and providers (performance bias), blinding of outcome
assessor (detection bias), incomplete outcome data (attrition bias),
selective outcome reporting (reporting bias), and other sources of
bias. The first part of the tool involves describing what was re-
ported to have happened in the study. The second part of the tool
involves assigning a judgement relating to the risk of bias for that
entry, in terms of either low, high, or unclear risk. We used the
criteria indicated by theCochrane Handbook for Systematic Reviews
of Interventions adapted to the addiction field.
We assessed the domains of sequence generation and allocation
concealment (avoidance of selection bias) using the ’Risk of bias’
tool by a single entry for each study.
We considered blinding of participants, personnel and outcome
assessor (avoidance of performance bias and detection bias) sep-
arately for objective outcomes (e.g. drop out, use of substance of
abuse measured by urine-analysis, subjects relapsed at the end of
follow-up, subjects engaged in further treatments) and subjective
outcomes (e.g. duration and severity of signs and symptoms of
withdrawal, patient self-reported use of substance, side effects, so-
cial functioning as integration at school or at work, family rela-
tionship). Blinding of participants and personnel was generally not
feasible given the type of intervention, so we did not consider this
item. In addition, we assessed detection bias based on blinding of
outcome assessors.
Incomplete outcome data (avoidance of attrition bias) was con-
sidered for all outcomes except for drop out from the treatment,
which is very often the primary outcome measure in trials on ad-
diction. We also considered whether exclusion criteria could be a
source of bias and if intention-to-treat analysis was used.
Measures of treatment effect
For most of the included studies, retention and abstinence out-
comes were reported in terms of proportion (given as a percent) of
participants in each intervention arm to have specific outcomes.
When possible, we analysed the results as dichotomous outcomes
(e.g. retention vs. non-retention in treatment) and reported them
as a risk ratio (RR) with a 95% confidence intervals (CIs).
Dealing with missing data
When questions regarding data arose, we contacted the primary
study author. We attempted to contact six study authors and four
responded. However, none had data that would have allowed ad-
ditional analyses.
Assessment of heterogeneity
We analysed heterogeneity by means of the I2 statistic and Chi2
test for heterogeneity. The cut-off points were: I2 statistic value >
50% and the Chi2 test P < 0.1. Also, we evaluated the occurrence
of heterogeneity and reported it qualitatively for included studies
because of variability between chosen control populations in dif-
ferent studies. For the outcomes measured, different studies used
many types of control groups including pharmacological, placebo,
and other psychosocial interventions.
Data synthesis
We combined the RR value from each trial through meta-analysis
using a random-effects model. Otherwise, we reported the mean
difference for outcomes that measured average measures (birth
weight and days hospitalized after delivery).
Sensitivity analysis
We did not use methodological quality as a criterion for trial in-
clusion. However, in order to assess the effect of the low quality
studies we planned to do a sensitivity analysis, either including or
excluding the studies at high risk of bias from meta-analysis.
R E S U L T S
Description of studies
Results of the search
The original Cochrane review yielded 263 records of which 44
were considered eligible and were reviewed as full texts (Terplan
2007).We included a total of nine articles. Updated searches done
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in January 2015 identified a further 385 papers.We screened these
articles by title/abstract and of these we retrieved and assessed
21 full text articles. We included five of these trials. In total we
included 14 trials in this review update (Figure 1).
Figure 1. Study flow diagram.
Included studies
Fourteen RCTs (1298 participants) met the inclusion criteria. All
included studies were in the English language. For substantive
descriptions of each of the included trials see the Characteristics
of included studies section.
Trial duration
The duration of the included trials ranged from 14 days to 24
weeks.
Participants
We included a total of 1298 participants. Thirteen trials reported
age and the mean age for those was 28.8 years. Two trials did not
report the ethnicity of participants (O’Neill 1996; Yonkers 2012).
All but three RCTs had a majority of African American partici-
pants. Carroll 1995 did not report ethnicity specifics, but most
participants were non-minority (11/14, 78.6%). Mullins 2004 re-
ported 50% of participants were Caucasian and only 33% were
African American. Winhusen 2008 reported 34.7% participants
were African American women and 39.7%were Caucasian. Of the
trials that reported ethnicity, on average 63.12% of participants
were African American. All trials but O’Neill 1996 and Yonkers
2012 reported marital status. Overall, 79.8% of participants were
single, never married, or divorced. All trials except O’Neill 1996
reported employment status for all participants. Overall, 88.6%
of the trial participants were unemployed. Three studies did not
report the educational level of participants (Carroll 1995; Jones
2001; Mullins 2004). Of the remaining studies, most participants
had at least some high school education, either measured as a pro-
portion (> 50%) or > 10 mean years of education. In Haug 2004,
most participants had less thanhigh school education (94%).Most
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trials did not mention gestational age at enrolment. Of the re-
maining trials, on average participants were enrolled during the
second trimester, with the exception of Carroll 1995 in which the
average gestational age was eight (± 6) weeks.
All but four studies (Carroll 1995; Winhusen 2008; Jones 2011;
Tuten 2012a) used the Diagnostic and Statistical Manual of Men-
tal Disorders (DSM-III-R or DSM-IV-R) criteria in the assess-
ment of substance use among participants. With Carroll 1995, all
participants can be assumed to be opioid dependent as they were
receiving methadone maintenance. Many were also using cocaine
(mean days of cocaine = 2.7 in 30 days prior to enrolment). Jones
2011 included participants if they had self-reported heroin or co-
caine use in the past 30 days. Participants reported an average of
14.9 days of opiate use over the past 30 days and an average of
13.4 days of cocaine use over the past 30 days. For Winhusen
2008, participants were identified by the participating treatment
programmes as requiring substance abuse treatment, and no men-
tion of DSM-III-R criteria was made. In Tuten 2012a, partici-
pants had an average of 13.4 days of use in the past 30 days for
cocaine and 14.9 days of use in the past 30 days for opiates. In the
remaining nine RCTs, 70% of participants were cocaine depen-
dent, and 66.9% were opiate dependent. Only Mullins 2004 had
no heroin-using participants. Seven studies recorded both mari-
juana and alcohol use (O’Neill 1996; Svikis 1997; Jones 2001;
Silverman 2001; Haug 2004;Mullins 2004; Svikis 2007). Within
these studies, 23.7% of participants were marijuana dependent,
and 17.9%were alcohol dependent.Only two trials recorded nico-
tine dependence (O’Neill 1996; Haug 2004), which was 99%. All
included RCTs had high compliance with reporting.
Setting and country of origin
All included RCTs took place in the USA except for O’Neill 1996,
which took place in Australia. All trials took place in drug treat-
ment facilities that were either academic-based, or hospital-based,
or both. All included trials were predominately in the outpatient
setting. Five studies began in an inpatient setting (Jones 2000;
Jones 2001; Svikis 2007; Jones 2011; Tuten 2012a) during which
time randomization took place. All participants in these trials tran-
sitioned to outpatient management after seven days where they re-
ceived the study intervention. Several trial sites provided free trans-
portation and childcare to their participants. Jones 2000, Jones
2011, and Tuten 2012a also included on-site PNC and psychi-
atric consultation. Mullins 2004 described their centre as provid-
ing “gender-specific” treatment.
Study size
Study sizes ranged from 12 to 168 participants.
Types of interventions
Trials fell into two types of experimental interventions: nine with
704 participants used CM (Carroll 1995; Svikis 1997; Elk 1998;
Jones 2000; Jones 2001; Silverman 2001; Svikis 2007; Jones 2011;
Tuten 2012a), and five with 594 participants used MIB methods
that involvedmotivational approaches (O’Neill 1996;Haug 2004;
Mullins 2004; Winhusen 2008; Yonkers 2012).
With the exception of Silverman 2001 and Jones 2011, all RCTs
appliedCM in the formofmonetary vouchers. In Silverman 2001,
the concept of abstinent reinforcement contingencies were inte-
grated into an employment setting referred to as the Therapeutic
Workplace. The participants received work and salary only when
they remained abstinent. For Jones 2011, CM methods were ap-
plied to housing. A key piece of the treatment plan in this study
involved abstinence-contingent housing.
Among the included trials, vouchers were tied to negative urine
toxicology (Carroll 1995; Silverman 2001; Jones 2011; Tuten
2012a), treatment attendance (Svikis 1997; Svikis 2007), or both
(Elk 1998; Jones 2000; Jones 2001). Although the original appli-
cations of CM to substance treatment involved a schedule of esca-
lating reinforcement for sustained behaviours (e.g. Higgins 1991),
only Jones 2000, Jones 2001, Svikis 2007, and Tuten 2012a used
an escalating schedule.
Ten trials provided psychosocial interventions in addition to com-
prehensive usual care that included pharmacological treatment
such as methadone maintenance, counselling, PNC, STD coun-
selling and testing, transportation, and/or childcare (Carroll 1995;
O’Neill 1996; Svikis 1997; Elk 1998; Jones 2000; Silverman
2001;Haug 2004;Mullins 2004; Jones 2011; Tuten 2012a). Eight
RCTss (Carroll 1995; O’Neill 1996; Svikis 1997; Jones 2000;
Silverman 2001; Haug 2004; Jones 2011; Tuten 2012a) also had
patients in both the intervention and control groups receive meth-
adone maintenance treatment (MMT).
For the control interventions, eight studies utilized usual care or
comprehensive usual care (O’Neill 1996; Elk 1998; Jones 2000;
Jones 2001; Silverman 2001; Haug 2004; Winhusen 2008; Jones
2011). Five of the fourteen studies used other psychosocial inter-
ventions for the control group (Carroll 1995; Svikis 1997;Mullins
2004; Tuten 2012a; Yonkers 2012).O’Neill 1996 used onlyMMT
with the control group and no other interventions.
Excluded studies
We excluded 52 studies in total from this review. The reasons
for exclusion were: study design did not meet inclusion criteria
(i.e. it was not a RCT) (37 studies); study participants did not
meet inclusion criteria, either not pregnant or not in treatment
(seven studies); paper was a re-analysis of already published data,
in this case the primary paper that matched the inclusion criteria
best was included (four studies); or intervention was not within
the scope of the review (three studies). For further details, see the
Characteristics of excluded studies section.
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Risk of bias in included studies
Allocation
Only five studies reported an adequate method of randomization
and were judged as having low risk of selection bias (Jones 2001;
Silverman 2001; Winhusen 2008; Jones 2011; Yonkers 2012). In
Jones 2001, randomization was performed via coloured chip selec-
tion from a hat (with replacement of the chip following each selec-
tion). Jones 2011 and Yonkers 2012 used a computer programme
to generate randomized assignments. In Silverman 2001, a mod-
ified dynamic balanced randomization (Signorini 1993) was used
to randomize patients sequentially to the treatment conditions.
Winhusen 2008 used an urn randomization protocol, the details
of which are limited, but which was likely sufficient to limit risk
of bias. All other included trials simply reported that the groups
were randomized, so were judged as having unclear risk of bias.
Only two trials adequately described an adequate method of allo-
cation concealment (Jones 2011; Yonkers 2012). The remainder
did not describe a method for allocation concealment and were
judged as having an unclear risk of bias.
Blinding
Blinding of participants and providers was not considered because,
given the type of interventions reviewed, blinding of the study
participants and providers was impossible. There was only one
mention in the included RCTs as to whether the outcomes were
assessed in a blinded fashion. O’Neill 1996 stated that follow-up
assessmentswere conducted by an interviewerwhowas blind to the
participants’ assignments. Yonkers 2012 used an objectivemeasure
(urine toxicology) unlikely to be biased by lack of blinding. All
other RCTs were judged as having an unclear risk of detection
bias.
Incomplete outcome data
Seven studies were judged to have low risk of bias (Elk 1998;
Jones 2001; Silverman 2001; Svikis 2007; Winhusen 2008; Jones
2011; Yonkers 2012). Carroll 1995 and Haug 2004 were judged
as high risk of attrition bias. The other trials did not provide
information about attrition from the study and were judged as
having an unclear risk of bias
Other potential sources of bias
All included trials collected and reported baseline characteristics,
such as demographic data. This allowed for the comparison of the
study sample between intervention and control groups in all but
two trials. Svikis 1997 reported information stratified by metha-
done maintenance status. Therefore, it was impossible to evaluate
differences between intervention and control groups. Svikis 2007
only provided summary statistics for the entire study group, and
we were unable to separate them by intervention vs. control group
assignment. In the remaining studies, the groups were judged to
be similar in terms of baseline drug use. With the exception of
Haug 2004, demographic data between the groups were similar.
In Haug 2004, the groups differed with respect to race; there was a
higher proportion of Caucasians in the intervention group (23%
vs. 6%).
We have provided summary figures related to the risk of bias of
included studies (Figure 2; Figure 3).
Figure 2. Risk of bias graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
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Figure 3. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
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Effects of interventions
See: Summary of findings for the main comparison Summary
of findings table 1
We considered the following types of comparisons:
• Comparison 1: Any psychosocial vs. control, 14 RCTs,
1298 participants (Carroll 1995; O’Neill 1996; Svikis 1997; Elk
1998; Jones 2000; Jones 2001; Silverman 2001; Haug 2004;
Mullins 2004; Svikis 2007: Winhusen 2008; Jones 2011; Tuten
2012a; Yonkers 2012);
• Comparison 2: CM vs. control, nine RCTs, 704
participants (Carroll 1995; Svikis 1997; Elk 1998; Jones 2000;
Jones 2001; Silverman 2001; Svikis 2007; Jones 2011; Tuten
2012a);
• Comparison 3: MIB vs. control, five RCTs, 594
participants (O’Neill 1996; Haug 2004; Mullins 2004;
Winhusen 2008; Yonkers 2012).
We summarized the results and compared them quantitatively
when possible.
Comparison 1: Any psychosocial Intervention vs.
control neonatal outcomes
See Summary of findings for the main comparison.
Neonatal outcomes
Neonatal outcomes were rarely captured. Four RCTs reported
neonatal outcomes (Carroll 1995; Elk 1998; Jones 2011; Yonkers
2012).
Preterm birth
Three trials (Elk 1998; Jones 2011; Yonkers 2012) with 264 par-
ticipants (RR 0.71, 95% CI 0.34 to 1.51; three trials, 264 partici-
pants; Analysis 1.1) showed no difference in preterm birth. Carroll
1995 measured median gestational age at delivery. Women in the
intervention group (both contingency management and motiva-
tional interviewing methods) had slightly longer gestations (40 vs.
38 weeks) than the control groups. Null hypothesis testing was
not provided and our attempts to obtain further data from trial
authors were not fruitful.
Positive neonatal toxicology at delivery
One trial (Jones 2011) with 89 participants (RR 1.91, 95% CI
0.86 to 4.24; one trial, 89 participants; Analysis 1.2).
Low birth weight
One trial (Yonkers 2012) (RR = 0.72, 95% CI 0.36 to 1.43; one
trial, 160 participants; Analysis 1.3) showed no difference in low
birthweight.Carroll 1995measuredmedianbirthweight.Women
in the intervention group had heavier infants (3.348 gm vs. 2.951
gm). Null hypothesis testing was not provided and our attempts
to obtain data from the trial authors were not fruitful.
Days hospitalized after delivery
Two studies (Carroll 1995, Jones 2011) (RR = -1.27, 95% CI -
2.52 to -0.03; two trials, 103 participants; Analysis 1.4; Figure
4) showed a decrease in days hospitalized after surgery. Elk 1998
stated that there was no difference in length of hospital detoxifica-
tion for newborns between the intervention and control groups,
althoughmean days or other summary statistics were not reported.
Figure 4. Forest plot of comparison: 1 Neonatal outcomes any psychosocial intervention vs. control,
outcome: 1.5 Mean days hospitalized after delivery.
Adverse events
Elk 1998 reported adverse perinatal events between the groups
(although “adverse perinatal events” were not clearly defined). No-
body in the intervention group had an adverse event, whereas 80%
of the control group did: two had preterm labour and two deliv-
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ered pre-term (prior to 37 weeks). However, this difference was
not statistically significant (P = 0.22).
Comparison 2: Any psychosocial Intervention vs.
control neonatal outcomes maternal outcomes
Maternal drug use measured by maternal toxicology
All but two included trials reported that urine toxicology was mea-
sured (Svikis 1997; Svikis 2007). However, only three RCTs in-
cluded these data. We received raw data from the authors of Haug
2004 but were unable to incorporate these data into the meta-
analysis. The authors of Winhusen 2008 measured positive urine
toxicology at onemonth of treatment (25.4% - intervention group
vs. 27.8% - control group) and at treatment completion (16.7%
intervention and 14.3% control). Jones 2011 and Yonkers 2012
also captured urine toxicology at the end of treatment. We per-
formed ameta-analysis from the available data for these three stud-
ies (Winhusen 2008; Jones 2011; Yonkers 2012): RR 1.14, 95%
CI 0.75 to 1.73; three trials, 367 participants; Analysis 2.1). Pool-
ing urine toxicology results at delivery only (Jones 2011; Yonkers
2012) (RR 1.18, 95% CI 0.52 to 2.65; two trials, 217 partici-
pants; Analysis 2.3).Overall for the four trials that employedMIB,
there were no differences related to substance use. Among the trials
employing CM, two trials showed a reduction in drug use mea-
sured by urine toxicology although the magnitude of this reduc-
tion was minimal and transient (Jones 2001) or difficult to assess
(Silverman 2001).
Retention at treatment completion
Ten trials measured retention at the end of study treatment
(O’Neill 1996; Svikis 1997; Elk 1998; Jones 2000; Jones 2001;
Haug 2004; Mullins 2004; Svikis 2007; Winhusen 2008; Jones
2011): RR 0.99 (95% CI 0.93 to 1.06; 10 trials, 819 participants;
Analysis 2.4).
Short term treatment retention
Early treatment retention was assessed by looking at retention
at longer than one month but less than the time of treatment
completion. Six RCTs including 514 participants had data beyond
one month but less than the end of treatment date (O’Neill 1996;
Svikis 1997; Elk 1998, Haug 2004; Mullins 2004; Winhusen
2008). The pooled estimates across these studies yielded: RR 1.00,
95% CI 0.90 to 1.10; six trials, 514 participants; Analysis 2.5. We
performed sensitivity analysis by excluding Mullins 2004, but this
did not alter the results.
Comparison 3 : CM interventions vs. control
For this comparison, only single studies addressed primary out-
comes and therefore meta-analysis was not possible.
Retention at treatment completion
As previously described in the aggregate retention at treatment
completion (Analysis 2.4), six studies utilizing CM interventions
reported information related to retention in treatment (Svikis
1997; Elk 1998; Jones 2001; Silverman 2001; Svikis 2007; Jones
2011). RR 1.03, 95% CI 0.92 to 1.16; six trials, 388 participants;
Analysis 3.3; Figure 5. Short term retention was described in two
different studies (Elk 1998 and Svikis 1997). RR 1.10 (95% CI
0.70, 1.73; 2 trials, 88 participants; Analysis 3.4).
Figure 5. Forest plot of comparison: 2 CM vs. control, outcome: 3.1 Retention in treatment at the end of
study.
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Comparison 4 : MIB interventions vs. control
Maternal drug use measured by maternal toxicology
Related to the primary outcome of positive urine drug tests at the
endof treatment only twoMIBmethod trials (Winhusen 2008 and
Yonkers 2012) had data, demonstrating no substantial difference
in urine toxicology between the MIB intervention groups and
the control groups. RR 0.96 (95% CI 0.63, 1.48; 2 trials 278
participants; Analysis 4.1)
Retention at treatment completion
Three trials provided data on retention in treatment using MIB
techniques (O’Neill 1996; Haug 2004; Winhusen 2008). Pooling
these data via meta-analysis resulted in: RR 0.97, 95% CI 0.89 to
1.06; three trials, 355 participants; Analysis 4.4).
D I S C U S S I O N
Summary of main results
We included 14 RCTs, nine that employed a form of CM and five
that used a manual-based intervention, namely MIB techniques.
We did not identify any trials that assessed other types of psychoso-
cial interventions. All interventions were compared with varied
comprehensive usual care control.
Our main interest was in both obstetrical and neonatal outcomes
of treatment. Illicit drug use is associated with a myriad of com-
plications for both the pregnant woman and her newborn. These
complications are costly and identifying a means of reducing their
prevalence would be beneficial. Unfortunately, the included RCTs
rarely reported on obstetrical or neonatal outcomes. Furthermore,
four trials listed obstetrical events, such as early delivery and mis-
carriage, as exclusion criteria. Only four trials reported birth out-
comes (Carroll 1995; Elk 1998; Jones 2011; Yonkers 2012). The
three CM trials showed a benefit with intervention. There was also
inconsistency between the studies with regards to the obstetrical
outcomes measured. Carroll 1995 and Jones 2011 measured both
mean gestational age and mean birth weight. However, Elk 1998
counted “adverse perinatal events”, a category that included both
preterm delivery, a serious obstetrical event, as well as preterm
labour, a clinical event of far less significance.
Eleven included trials reported continued illicit drug use, as mea-
sured primarily by urine toxicology. All trials had abstinence as a
goal of treatment except O’Neill 1996 which employed a harm
reduction model. This was also the only study which relied exclu-
sively on client self-report to assess continued drug use. The fre-
quency of urine sampling varied between studies, as did the meth-
ods of reporting the results. It was often unclear how the summary
proportions had been generated and, with the exception of Elk
1998, none mentioned statistical adjustment for multiple testing.
Overall, there appears to be little evidence that psychosocial in-
terventions reduce continued illicit drug use in pregnant women
enrolled in drug treatment. None of the trials that employedMIB
techniques reported an effect of the intervention on drug absti-
nence. Of the two RCTs that reported an effect, both employed
CM. However, the magnitude of the reduction was difficult to
assess (Silverman 2001), and its effect was small and temporary
(Jones 2001).
A primary goal of CM is to alter, if not to eliminate, drug use be-
haviours.Over the last decade, the clinical evidence demonstrating
CM efficacy in reinforcing drug abstinence has been established
(for a good summary see Sitzer 2006). This Cochrane review is
the first to specifically address drug treatment in pregnancy. It ap-
pears that the benefits of CM on drug abstinence are not as pro-
found in pregnant women as in the general population of people
in drug treatment. MIB methods in contradistinction have not
been shown to have consistent effects on subsequent abstinence
(Miller 2003) in drug treatment. Similarly, our results show no
benefit of MI in pregnancy, with a trend towards a negative effect.
Included trials reported retention in treatment most consistently
of all outcomes. As with any surrogate outcome, its clinical utility
is dependent upon the evidence of it as an intermediary to the
important clinical outcome (Grimes 2005). In pregnancy, atten-
dance in drug treatment has been shown to lead to increase birth
weight, increase in one minute Apgars, and overall lower costs
(Hubbard 1989; McCaul 1996; Svikis 1998). We found no dif-
ference in treatment retention either by CM or MIB techniques.
Psychosocial interventions, either CM or MIB, did not improve
treatment retention.
Overall, our Cochrane review identified few experimental studies
of psychosocial interventions in pregnancy for illicit drug use. This
is surprising given the wide use of such interventions in clinical
treatment. Furthermore, it is unlikely that manual based interven-
tions, such as MI, are used in isolation in clinical practice. Coun-
sellors most likely use different parts of multiple modalities simul-
taneously. Even if a particular psychosocial intervention is found
to be beneficial, its application may be limited by the realities of
drug treatment.
It is important to note that sites where these psychosocial treat-
mentswere delivered also included supplementary services for both
the experimental and control groups, including child care services,
transportation, and housing. These additional services are likely
to have contributed an overall effect to drug treatment outcomes,
hence the differential contribution of the psychosocial interven-
tion might have been difficult to observe. The drug treatment lo-
cations fromwhere this review’s data were obtained are likely more
comprehensive than standard drug treatment centres that enrol
pregnant women. We cannot assess whether psychosocial inter-
ventions in the absence of these additional services are beneficial
to pregnant women.
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Overall completeness and applicability of
evidence
There were several limitations of the included RCTs. Overall tri-
als were heterogeneous, differing in the details of both the inter-
vention and the control, and employing different lengths of treat-
ment. Some studies were quite small and likely underpowered, es-
pecially for obstetrical outcomes. The study settings were all sim-
ilar (academic specialist drug dependence units primarily in the
USA), as were the included participants. Although this decreases
heterogeneity between trials, the results of this review may not be
generalizable to other settings.
One of the limitations to CM is the cost. On average, CM par-
ticipants in the included trials cost up to $1364 per client (Tuten
2012a). Clearly this limits the applicability of CM on a large scale.
For this reason non-cash incentives, such as vouchers, have been
used. Silverman 2001 extended this concept to include job train-
ing.
It is important to acknowledge that many pregnant women are re-
ferred to drug treatment from the criminal justice system (Terplan
2010). Unfortunately, no included trials discussed the referral pat-
tern of their respective patient populations. Manual based inter-
ventions, such as MI, are likely less effective among coerced peo-
ple. In fact, they may be counterproductive. Actively engaging
a pregnant woman before she is ready to change may be detri-
mental, especially when the intervention involves MIB techniques
(Hettema 2005).
It is also important to note the characteristics of the included par-
ticipants. The patients were overwhelmingly unemployed, poor,
African American, and with low education levels. This limits the
generalizability of the study results. The population of women
who use illicit drugs in pregnancy is different from those enrolled
in drug treatment, which differs from the population of women
in treatment who participate in experimental trials. In general, the
efficacy of psychosocial interventions may vary between these dif-
ferent patient subsets.
Quality of the evidence
The quality of reporting in the included studies was very poor
so that for most items and studies a judgment of unclear risk of
bias was given. A recurring issue was an observed heterogeneity
between the included trials in terms of outcomes measurements.
For example, trials measured urine toxicology differently (and at
different time points). Similarly, retention in treatment definitions
varied and were assessed at different time points between studies.
See also Summary of findings for the main comparison.
Potential biases in the review process
The data extraction and input process were consensus driven and
several review authors verified this independently. We believe that
we identified all relevant studies as we searched the grey literature,
and contacted trial authors and field experts. However, we were
unable to obtain additional data from some trial authors which
would have enriched analysis of neonatal and urine toxicology
outcomes. Given the absence of any effect of the interventions on
retention or urine toxicology, it is unlikely that these additional
data would have changed our summary meta-analysis.
Agreements and disagreements with other
studies or reviews
Since our first version of this Cochrane review (Terplan 2007), no
other systematic reviews have been performed on this topic.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
In conclusion, psychosocial interventions when taken in the pres-
ence of other comprehensive care options do not translate into
better neonatal or obstetrical outcomes, nor are they associated
with greater illicit drug abstinence or increased treatment retention
among pregnant women. The included trials rarely captured ma-
ternal and neonatal outcomes and there was no data on cost bene-
fit. Though psychosocial interventions were found to reduce days
neonates were hospitalized after delivery, it is unclear if this ob-
servation is reflective of real effect or delivery practices. Therefore,
there is insufficient evidence to evaluate the effect of psychoso-
cial interventions on birth or neonatal outcomes among pregnant
women in treatment. Overall, the current quality of evidence was
low tomoderate and future studies shouldmeasure these outcomes
systematically.
Implications for research
Large RCTs with obstetrically meaningful endpoints and longer
follow-up times are required to examine whether psychosocial in-
terventions help pregnant women with illicit drug dependence.
Poor obstetrical outcomes should not be exclusion criteria to study
participation, as these events are essential to capture as theymay be
related to illicit drug use. Ideally these studies should havemultiple
sites in order to capture a greater diversity of study patients which
would increase the generalizability of the findings. The reporting
of criminal justice referral into treatment is especially important,
as the efficacy of psychosocial interventions may be different be-
tween people who have been coerced into treatment and those
who enter voluntarily.
Questions that should be considered include:
• Is one psychosocial intervention more effective than
another?
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• What covariate, such as drug use history, time in treatment,
or gestational age upon enrolment, are associated with treatment
effectiveness?
• What is the optimal reimbursement for CM and its overall
cost effectiveness?
Overall the trials should state clearly themethod of randomization
and allocation concealment. Although blinding of participants is
impossible, those assessing outcomes and performing the analyses
should be blinded (and this should be clearly stated). Intention to
treat (ITT) analysis should be performed and power calculations
used a priori.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Carroll 1995
Methods RCT.
No difference between groups on baseline drug use or demographic characteristics
Participants 20 pregnant women enrolled in methadone maintenance. Mean age 27.6; 78.6% non-
minority (11/14); 78.6% single; 100% unemployed; 8(± 6) weeks gestational age upon
entry into MMT; 2.7 mean days cocaine use in past 30 days. Exclusion: > 28 weeks
pregnant
Interventions Daily MMT, weekly group counselling, three times/week urine toxicology screening for
all participants
1. Weekly prenatal classes, weekly relapse-prevention groups, childcare during
treatment visits, and CM awards - USD15/ week for three consecutive negative urine
screens (n = 7).
2. MMT and weekly group counselling (n = 7).
No difference between groups in terms of MMT dose (mean 50 mg).
Duration: average 23 weeks (range 13 to 31 weeks).
Outcomes Attendance was measured in terms of % number of groups attended. Infant outcomes
measured as mean gestational age at delivery, mean weight, and mean number of days in
the hospital. Urine toxicology was measure as % positive for cocaine, opiates, or other
drugs
Notes Unable to measure retention as not reported. We attempted to contact trial authors but
data was unavailable
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “a total of 20 women provided informed
consent and were randomly enrolled…”
No details were provided related to ran-
domization methods.
Allocation concealment (selection bias) Unclear risk Allocation concealment was not described.
Incomplete outcome data (attrition bias)
All outcomes
High risk “A total of 20 women provided informed
consent and were randomly enrolled. Of
these, one delivered within 1 week of pro-
viding consent, one was hospitalized for
sedative detoxification, and four, all of
whom had been on the methadone pro-
gramme for several months or years when
they became pregnant, did not participate
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Carroll 1995 (Continued)
in any groups or study assessments andwere
considered dropouts.”
20 patients randomized and only 14 anal-
ysed. 6 dropouts (unclear from which ran-
domized groups). Exclusions in analysis
were lost to follow-up because they did not
attend meetings or because of early labour.
These are all possible outcomes of the re-
view and their exclusion biases results. Also
analysis was per protocol not ITT
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk No references to outcome assessor blinding
made.
Elk 1998
Methods RCT.
Participants 12 cocaine-dependent pregnant women: 58% African American, 8% Hispanic, 33%
White; 92% never married or separated/widowed/divorced; 75% high school; 83%
unemployed; 67% gravida 5 or more, 25% gravida 3 to 4; 75% in second trimester;
DSM-III-R: 92% (10/11) cocaine primary drug of abuse, 8% (1/11) both heroin and
cocaine dependent
Exclusion: Cessation of cocaine use greater than 30 days prior to enrolment
Interventions All received PNC, behaviourally-based drug counselling, nutritional education, andHIV
counselling
1. CM, $18 for each cocaine-free urine sample, $20 weekly bonus if all 3 samples
negative and perfect attendance (including PNC) (n = 6).
2. Routine care. Duration unclear (at least 4 weeks) (n = 6).
Outcomes Retention in treatment as number remaining in treatment. Abstinence as average of
individual %. Attendance in PNC as number of visits. Perinatal outcomes as number
of preterm labour, or preterm delivery, or both. ASI composite scores presented as a bar
graph. All outcomes reported as chi square with P value only when significant
Notes Treatment facility provided free transportation and child care. We attempted to contact
trial authors but received no response
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “Following stratification on referral source (self vs. court or pro-
bation or parole), subjects were randomly assigned to one of two
treatment groups…”
No details provided related to randomization methods.
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Elk 1998 (Continued)
Allocation concealment (selection bias) Unclear risk Allocation concealment not described.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Attrition details outlined for the 12 women, all 12 carried
throughout the analysis. Results have detailed participant num-
bers for each outcome
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk No references to outcome assessor blinding made.
Haug 2004
Methods RCT.
Groups significantly different for race. No difference in drug use and psychiatric comor-
bidity
Participants 77 pregnant opioid-dependent women randomized with 14 disqualified post-random-
ization, ≤ 26 weeks gestational age, receiving MMT and ≥5 cigarettes/day. Mean age
29.7; 84% African American; 79% single or never married; 97% unemployed; 94%
less than high school education. DSM-III-R: all heroin dependent (100%), 41 (35%)
cocaine dependent, 10 (16%) marijuana dependent, 17 (27%) alcohol dependent, all
(100%) nicotine dependent
Exclusion criteria: not stated.
Interventions For all MMT, no information on urine monitoring, or counselling/therapy. All received
USD 10 voucher after initial battery and USD20 when 10-week interview completed.
Mean MMT dose 65.2 mg. All received PNC and substance abuse counselling - no
details described
1. Four MET sessions using a modification of the Project MATCH MET manual
(Miller et al., 1995). Visit 1 - rapport building; visit 2 (1 week later) - personalized
feedback on positive behaviours, negative consequences of smoking, and stage of
change; visit 3 (week 4) - commitment and plan for change developed; visit 4 (week 6)
- barriers to long-term change addressed (n = 30 post disqualification).
2. Standard care advice (no specific details related to content provided) (n = 33 post
disqualification).
Duration 10 weeks.
Outcomes Retention in treatment as % attrition. Stage of change and stage movement. Urine
toxicology done at the 10-week follow-up
Notes Randomization occurred during residential treatment.
14 disqualified post randomization for spontaneous abortion. 21 excluded for reasons
not stated.
We received raw data for urine toxicology after contacting the trial authors for informa-
tion
Risk of bias
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Haug 2004 (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “Seven women refused study participation
and 77 patients completed baseline assess-
ment and were randomized”
No specific methods for randomization
outlined.
Allocation concealment (selection bias) Unclear risk Allocation concealment not described.
Incomplete outcome data (attrition bias)
All outcomes
High risk “At the 10-week follow-up, participant at-
trition was 14% (n = 9), with missing par-
ticipants evenly distributed between the
MET (n = 4) and SC (n = 5) groups. The
only difference between completers and
those lost at follow-up was average meth-
adone dose during treatment (M=50.8mg
vs. 36.3 mg, respectively), t(61)=-6.34,p<.
0001.”
Some information was provided related to
attrition (total number of individuals who
dropped out). Outcome measures did not
explicitly state the number of participants
analyses were based on. Furthermore, de-
tails were not provided related to which
groups the initially disqualifiedparticipants
came from,making attrition data more un-
clear
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk No mention of blinding of outcome asses-
sors.
Jones 2000
Methods RCT.
No difference between groups on baseline drug use.
Participants 93 pregnant women enrolled in substance use treatment, 18 years of age or older,meeting
DSM-III-R criteria. Average age 28.9; 88%African American; 75% single; 50% less than
HS education; 97% unemployed; DSM-III-R: 75% cocaine dependence, 74% opiate
dependence, 50% both; 25 women (27%) received MMT
Exclusion criteria: not stated.
Interventions For all participants, treatment services included a 7-day residential stay followed by a 30-
day intensive treatment (7 days/week, 6.5 hours/day). For individuals receiving MMT,
no information on doses
1. 5$ incentives given out during the first 7 days of outpatient treatment (n = 53).
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2. 0$ incentives given.
ForMMT subgroup: could receiveUSD5 for each negative urine andUSD25 or USD50
bonus for 5 or 7 days drug-free urine, and additional USD20 if completed all urine
samplings and or attendance card monitoring. For nonMMT: USD5 each day attended
at least 4 hours treatment, USD25 or USD50 bonus for attending 5 to 6 or 7 days. (n
= 40)
Duration: 37 days.
Outcomes Attendance was measured in days and hours. Urine toxicology was not reported. Reten-
tion or loss to follow-up was not reported
Notes Transportation and childcare provided.
Although randomized to incentive vs. no incentive, the nature of the disbursement of
the incentives varied between MMT and not MMT subgroups.
We contacted the trial author who was unable to provide original data
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “On admission, both MM and AT subjects
were recruited and randomly assigned to
one of two incentive conditions…”
No explicit methods of randomization out-
lined.
Allocation concealment (selection bias) Unclear risk Allocation concealment not described.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk No details related to attrition provided.
Nodetailed results included, unclear which
participant numbers outcomes are based on
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk No references to outcome assessor blinding
made.
Jones 2001
Methods RCT.
No difference between groups on baseline drug use or demographic characteristics
Participants 80 pregnant women on MMT, greater than 18 years of age, meeting DSM-II-R criteria
for opiate dependence with cocaine abuse, admitted for first time for substance abuse
treatment.Mean age 28; mean gestational age 23.4; 96% unemployed; 85% single/never
married; 76% African American; 20% chronic medical conditions (HTN, DM, HIV);
DSM-III-R: 100% opiate dependent, 69% cocaine, 5% marijuana, 10% alcohol
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Interventions For all participants treatment consisted of a 7-day residential followed by 7 days of inten-
sive outpatient (7 days/week, 6.5 hours/day). Treatment consisted of group counselling
and at least once a week individual psychotherapy. All received MMT, mean dose 42
1. Money vouchers could be earned for specific target behaviour: attend at least 4
hours counselling and (days 8-14) provide a cocaine negative urine sample (n = 44).
2. No voucher incentives (n = 36).
Duration 14 days.
Outcomes Attendance was measured as mean full day attendance as well as “perfect treatment
attendance” defined as attendance on at least 13 or 14 full days of treatment. Retention
was measured as the % drop out. Urine samples were collected daily from days 8 to 14
and reported as % positive
Notes Transportation, child care, on site PNC and psychiatric consultation provided.
We contacted the trial authors who were unable to provide raw data
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Randomization procedure involved pa-
tients selecting one of two different color
chips from a hat with replacement follow-
ing each selection…”
Specific process outlined that provides par-
ticipants with equal chance of assignment
Allocation concealment (selection bias) Unclear risk Allocation concealment was not described.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Attrition data specified and descriptions of
different analytic methods to account for
missing data outlined
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk No references to outcome assessor blinding
made.
Jones 2011
Methods RCT.
Participants 89 women at least 18 years old, with a single fetus, self-reported heroin or cocaine use
in the past 30 days, completion of a 7-night inpatient stay on an assisted living unit and
willingness to live in recovery housing or other drug-free housing.
Interventions Both groups received usual care involving group and individual counseling and psychoe-
ducation, medically-assisted withdrawal for patients either refusing methadone main-
tenance or not meeting current opioid dependence criteria, methadone maintenance
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for qualifying opioid-dependent patients, care management, obstetrical care, psychiatric
evaluation and treatment, general medical management
1. Reinforcement based treatment (RBT) included usual care as well as treatment
planning, behaviour graphing, weekly recreational, vocational, and peer reinforcement
groups (n = 47).
2. Usual care without any additional services (n = 42).
Outcomes One month post-randomization treatment outcomes included days retained in CAP
treatment before delivery. Measures at baseline and 1 month after: number of days in
recovery housing; heroin and cocaine use; employment status; illegal activity. Maternal
and neonatal outcomes at delivery:Maternal: enrolment at CAP at delivery; urine screen-
ing positive for any illegal drug at delivery. Neonatal outcomes: estimated gestational age
at delivery; prematurity (< 37 weeks); birth weight, number of days of hospitalization
after birth
Notes On-site child care and paediatric care also provided to all participants
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “random assignment of participants to one of the two treatment
conditions was performed by a staff member with no participant
contact who generated a random condition assignment with a
computer program…”
Type of computer programme is unknown, but was likely suffi-
cient for randomization
Allocation concealment (selection bias) Low risk “random assignment of participants to one of the two treatment
conditions was performed by a staff member with no participant
contact who generated a random condition assignment with a
computer program…”
Staff member had no contact with participants.
Incomplete outcome data (attrition bias)
All outcomes
Low risk From caption of Figure 1: “All analyses reported in this paper are
based on the data from these 89 participants and their respective
89 neonates”
Detailed attrition data with flowchart. 89 patients randomized
and 89 patients data at follow-up
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk No mention of blinding of outcome assessors.
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Methods RCT.
No difference between groups in baseline drug use.
Participants 71 pregnant women who used illicit drugs in pregnancy, aged 18 years or older. (1) 35
(2) 36. Average age 27.1; 73% single/never married; 88% unemployed; 82% receiving
government income; 32% African American, 50%Caucasian; DSM-III-R: 49% cocaine
dependent, 28% marijuana, 4% alcohol
Exclusion: no obvious impairment (acute psychosis or organic illness)
Interventions For all participants, substance treatment counselling provided. Nature of counselling not
elaborated
1. 3 MI sessions (at the time of intake, 1 week following, and 2 months after
completion). No manual was used. Session done by four mental health providers all
with formal training in MI (n = 35).
2. Educational control group received 30 minute educational video at intake and at
one week and 60 minute home-visit at 2 months (n = 36).
Study duration 2 months.
Outcomes Attendance reported as number and % attended. Urine was screened at intake and then
randomly once per week and were reported as a mean proportion of negative screens
Notes Gender-specific treatment centre. Transportation and childcare included.
Treatment integrity and MI proficiency were evaluated. Likert scores used to asses inter-
rater reliability.
We attempted to contact the trial authors but received no answer
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk We used a stratified random sample proce-
dure based on ethnicity and drug of choice
(cocaine/crack cocaine, marijuana, am-
phetamine/methamphetamine, alcohol, or
PCP) to assign participants to conditions
Comment: No specific descriptions of ran-
domization methods were made
Allocation concealment (selection bias) Unclear risk No references to allocation concealment
procedures made.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Specific attrition data was not included.
Some information related to number of
sessions attended and no-show rates for
specific sessions were detailed, but overall
study attrition was not outlined clearly
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Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk No mention of blinding of outcome asses-
sors.
O’Neill 1996
Methods RCT.
Participants 92 pregnant women enrolled in MMT who injected drugs. Mean age 26.2; mean years
education 10.2; 53% ever sex worker; mean gestational age 22 weeks; DSM-III-R: 85%
opiate dependent, 15% cocaine, 59% marijuana, 32% alcohol, 98% nicotine
Interventions All participants received MMT (mean methadone dose 49 mg) and counselling about
HIV risk
1. 6 sessions of manual based CBT lasting 60 to 90 minutes, the first being more of
a MI (n = 47).
2. No intervention (n = 45).
Duration 9 months.
Outcomes Retentionwasmeasured as a proportion. Attendancewasmeasured as the average number
of missed appointments
Notes Researchers attempted to contact patients lost to follow-up through the Department of
Social Security and Department of Health.
We attempted to contact the trial authors but received no answer
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Study states that subjects were randomly allocated to the inter-
vention or control group, but does not outline specific random-
ization methods
Allocation concealment (selection bias) Unclear risk No specific references to allocation concealment methods were
made
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk “Five subjects dropped out of the intervention condition; three
before any sessions and four after two or more sessions. There
were no differences in any of the variables (demographic, drug
use or HIV-risk taking behaviour) between those who remained
in the study and those who dropped out. There were 40 subjects
in each group at the post-intervention assessment. Of these 80
subjects, 74 (92.5%) were contactable 9 months later. One
refused to participate further, giving a 91% follow-up rate of
those who complete pre- and post-intervention assessments.”
Attrition information provided, but differences between the in-
tervention and control group not detailed. In addition, specific
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participant numbers for different outcomes not stated
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk “Assessments occurred at pre-intervention, post-intervention
and at 9-month follow-up. Follow-up assessments were con-
ducted by an interviewer blind to the subject’s group member-
ship.”
Specific references to the blinding of the interviewer conducting
follow-up assessments makes the risk of detection bias low
Silverman 2001
Methods RCT.
Groups similar in terms of demographic and baseline drug use
Participants 40 pregnant, unemployed, women 18 to 50 years old on MMT, and with positive urine
toxicology for opiates within 6 weeks prior to enrolment. Mean age 32; 83% African
America; 65% HS or greater education; 7.5% married; 100% unemployed; 100% used
cocaine; 75% used cocaine.
Exclusion: at risk for suicide, psychiatric disorder.
Interventions For all participants, substance abuse counselling and MMT provided. Details of coun-
selling not given. No mention of MMT doses or schedule
1. Therapeutic workplace 3 hours/day for 6 months. Job skills training provided.
Base-pay voucher given out at the end of shift. Entrance to workplace contingent upon
negative urine sample. Job skills focused on data entry. Vouchers used to promote
abstinence and maintain workplace attendance (n = 20).
2. “Routine” drug treatment services provided by the centre. Details not given (n =
20).
Duration 24 weeks.
Outcomes Retention in treatment defined as remaining in the study through 24 weeks and reported
as N and %. Urine toxicology reported as % negative over total study period for each
group, and reported as overall positive and drug-specific positive. Attendance in Thera-
peutic Workplace was calculated and presented in a bar graph for each woman
Notes Transportation and childcare provided at no cost.
We attempted to contact trial authors but received no answer
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “A modified dynamic balanced random-
ization was used to randomize patients se-
quentially to the treatment conditions.”
Allocation concealment (selection bias) Unclear risk Allocation concealment was not described.
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Incomplete outcome data (attrition bias)
All outcomes
Low risk Attrition details outlined, reasons for leav-
ing also outlined. Different methods uti-
lized to attempt to account for missing data
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk No references to outcome assessor blinding
made.
Svikis 1997
Methods RCT.
Unable to assess baseline difference between groups as results reported in terms of MMT
vs. not MMT
Participants 142 pregnant women in a comprehensive substance abuse treatment programme, > 18
years of age, and whomet DSM-III-R criteria for opiate or cocaine dependence, or both.
Mean age 28.4; mean years of education 11; estimated gestational age 22 weeks; 53
(70%) unemployed; 81.4% single/never married; DSM-III-R: 79.6% used cocaine; 83.
8% used cocaine.
Exclusion: gestational age≥ 34 weeks, psychiatric disorder, delivered, or had miscarriage
during the study time
Interventions For all participants, treatment consisted of 7 days residential care followed by 30 days
of day treatment (7 days/week, 6.5 hours/day). Group counselling with once/week in-
dividual counselling. Obstetrics/Gynecology services on site. For individuals on MMT,
no mention of doses
1. USD5 or USD10 incentives/day for at least 4 hours of attendance/day. (Not
MMT n: 40, MMT not reported).
2. USD0 or USD1 incentives/day for at least 4 hour/day attendance. (Not MMT n:
36, MMT not reported).
Duration 30 days.
Outcomes Retention in treatment defined as remaining in treatment for 30 days and reported as
number of days. Mean number of days also calculated
Notes Results were not reported in terms of intervention vs. control group, rather in terms
of MMT vs. not MMT. All individuals were randomized to USD0, USD1, USD5 or
USD10 group, however USD0 and USD1 were grouped together as “control”. Only
USD5 and USD10 groups were analyzed as “intervention”.
We attempted to contact the trial authors but received no answer
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “Subjects were told that within 24 h prior
to transfer from residential to IDT, they
would be randomly assigned to one of the
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four incentive groups…”
No description of specific randomization
process used.
Allocation concealment (selection bias) Unclear risk Allocation concealment not described.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Only breakdown of methadone vs. non-
methadone maintained provided, limited
information related to incentive condition
assigned. Presumably data is for all random-
ized individuals, given fact that retention
and attendance are primary outcomes, un-
clear if this impacts outcomes
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk No references to outcome assessor blinding
made.
Svikis 2007
Methods RCT.
Participants 91 pregnant drug-dependent women enrolled in comprehensive drug use treatment
programme - 18 years of age or older who met the DSM-III-R criteria for opiate, or
cocaine dependence, or both.
Exclusion: Receivedmethadone pharmacotherapy, delivered prematurely or aborted dur-
ing study period, were administratively discharged from study, had extended or reduced
residential stays, had acute psychiatric distress that prohibited study participation
Mostly in early 30s, 74% single/never married, 84% African American, and 95% un-
employed, mean education of 11.2 years (SD = 1.9). 79.0% cocaine dependence, 37.
1% opiate dependence, 17.7% alcohol dependence, and 17.7% cannabis dependence
Interventions For all participants, treatment included 7 days of residential care followed by 30 days
intensive outpatient care.
1. Escalating voucher condition, also included an escalating voucher schedule for 14
days (starting at the first day of residential care). Participants had to attend a full day of
counselling (4 hours) to earn a voucher. Initial incentive values were USD5 for Day 1
and increased USD5 per day for each consecutive day of treatment attendance up to
USD70 for Day 14. Women could earn a maximum of USD525 for attending all 14
days of treatment. Participants were given one excused treatment day (n = 50).
2. Control: Routine care - 7 days residential followed by 30 days outpatient care (n =
41).
Outcomes Rate of premature residential treatment dropout against medical advice (AMA). Length
of stay in treatment. Mean days prior to AMA
Notes
Risk of bias
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Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “Those providing informed consent were randomly assigned to
either standard care or an escalating voucher schedule..”
No specific description of randomization process used.
Allocation concealment (selection bias) Unclear risk No mention of allocation concealment.
Incomplete outcome data (attrition bias)
All outcomes
Low risk As attrition is a primary outcome, incomplete data does not
seem to be an issue
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Blinding of outcome assessors not mentioned.
Tuten 2012a
Methods RCT.
Participants 222 pregnant women provided written consent, but 143 were randomized. Pregnant
women with an estimated gestational age of < 28 weeks who were opioid dependent and
methadone stabilized. Average of 30.0 years old (SD=5.2), 71.4%African American, 69.
9% never married, 11.6 (SD = 1.5) mean years of education, 6.0% currently employed.
Exclusion: not receiving methadone maintenance, non-compliant with study or CAP
procedures, had a miscarriage or terminated the pregnancy, transferred programmes, or
had a negative pregnancy test
Interventions 1. Escalating reinforcement condition, earned a USD7.50 voucher for the first
opioid negative and cocaine negative urine sample submitted. Voucher value increased
by USD1/day on the specimen collection days until delivery or until the participant
reached USD42.50 in earnings, after which earnings were capped and remained
constant at this amount. If relapse occurred no reward for positive urine sample and
value of voucher reset to USD7.50. Participants earned vouchers until delivery (n = 52).
2. Fixed reinforcement condition, participants received a USD25 voucher each time
they provided a drug-negative urine sample. Participants who remained drug abstinent
through the incentive period had total potential earnings of USD950. Earnings
continued if it occurred after week 13. A drug positive sample or missed urine sample
precluded voucher earnings, but earnings resumed upon submission of next drug free
sample (n = 38).
3. Attendance control condition, fixed and escalating participants were linked to an
attendance control participant. Each time the fixed or escalating reinforcement
participant received a voucher, the yoked participant received the same amount,
regardless of urine test results for that individual. Control participants were not aware
they were linked, but were told there was a chance that they might or might not be
paid for delivering urine samples (n = 43).
Study duration was 13 weeks or until delivery with 1 week of inpatient treatment (when
participants could earn two vouchers and 12 outpatient weeks during which participants
could earn three vouchers weekly)
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Outcomes Drug abstinence (number of urine screening tests negative for both opiates and cocaine,
number of negative urine tests prior to the first positive test and longest consecutive
number of negative urine tests), opioid use (with similar parameters as drug abstinence)
, cocaine use (with similar parameters)
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “participants were randomly assigned to one of the treatment
conditions within 5 days of program admission…”
No specific description of randomization used.
Allocation concealment (selection bias) Unclear risk No mention of allocation concealment processes.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk “Ten cases were missing data on one or more of the concomitant
variables so were dropped from the sample, reducing the final
sample to 133 cases.”
Some information about attrition given, but breakdown of as-
signment groups and attrition was not provided
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk No mention of outcome assessor blinding.
Winhusen 2008
Methods RCT.
Participants 200 women participating in the pregnant women treatment programmes at the four
participating community treatment programmes (CTPs). At least 18 years of age and
pregnant. Identified as needing substance use treatment via the CTP’s usual screening
procedure. Participantsmostly unmarried, unemployed, and had, on average, high school
education. Sample was fairly diverse in terms of race and ethnicity. Significant baseline
differences between the intervention and control participants. Intervention condition
had significantly older participants, significantly more minority participants, with sig-
nificantly more years of education, and with significantly more participants with cocaine
as their primary drug of choice (marijuana was primary drug of choice in the control
group). Exclusion: not pregnant, did not need to enter substance abuse treatment, un-
der 18, not interested in participating, had unstable living arrangements, had plans to
relocate within 4 months, pending legal charges, required inpatient treatment, suicidal/
homicidal risks, more than 32 weeks pregnant
Interventions 1. Three-session MET: rapport building, feelings discussion, reflective listening,
affirmation; followed by reviewing participants individualized personal feedback report
regarding consequences of substance use and pregnancy; lastly, developing change plan
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for participants who showed readiness and strengthening commitment for participants
not yet ready (n = 102).
2. Treatment as usual (TAU) that is usually provided by the CTP (standard
counselling sessions) (n = 98).
Active study phase was four weeks (three sessions of MET or TAU provided in the 28
day period)
Outcomes Treatment utilization, defined as ratio of number of outpatient treatment hours attended
to the number of hours scheduled. Number of weeks in which at least one treatment ses-
sion was attended. Number of weeks until treatment dropout, dropout defined as failure
to attend any treatment provided by the CTP for three consecutive weeks. Substance use
measured by self-report and qualitative toxicology results
Notes Participants in both conditionswere encouraged to participate in other treatment services
offered by the CTP (group treatment, case management)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Urn randomization to balance three dichotomous variables:
pressure to attend treatment, self report of drug and alcohol use
and need for methadone maintenance”
Unclear what type of urn randomization was used, but method
likely adequate
Allocation concealment (selection bias) Unclear risk Allocation concealment not described.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Attrition information provided (e.g. 200 randomized, 162 com-
pleted the 1-month active phase) and statistical analyses related
to attrition showed no difference between intervention and con-
trol group (P > 0.5)
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk No references to outcome assessor blinding made.
Yonkers 2012
Methods RCT.
Participants 183 women attending two hospital-based reproductive health clinics in Connecticut
between June 2006 and July 2010
Women met inclusion criteria if they: were aged > 16 years of age, were fluent in English
or Spanish, had not yet completed 28 weeks of pregnancy at screening, were planning to
deliver at a collaborating hospital, and using alcohol or an illicit drug other than opiates
during the 28 days prior to screening or scored at least a “3” on the modified TWEAK
survey
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Womenwere excluded if they: were already engaged in substance use treatment, endorsed
nicotine or opiates as their only substance, had plans to relocate, were not willing to
provide consent, were an imminent danger to themselves or their fetus, or if they required
inpatient general medical or psychiatric treatment
Interventions Women were randomized to one of two groups:
1. Women received MET with CBT provided by a nurse- six sessions delivered in
conjunction with prenatal and immediate postnatal care. Content included
motivational enhancement, communication skills, functional analysis, safe sexual
behaviour, relapse prevention, and problem-solving skills. Each of the six sessions lasted
approximately 30 minutes (n = 92).
2. Women received brief advice therapy (BA). BA involved brief counselling from an
obstetrical provider- manualized version of standard interventions offered by obstetrical
doctors and nurses. Counselling lasted about 1 minute and covered risks of substance
use, importance of abstinence, and the benefit of seeking drug and alcohol treatment
outside the prenatal setting (n = 91).
Outcomes Outcomes were assessed as measured at intake, delivery, and 3 months post-delivery
The primary outcome was the percentage of days of any alcohol or drug use in the prior
28 days
Secondary outcomesmeasured abstinence from substances (alcohol and drugs) according
to self-report, urine toxicology and combined self-report and urine. Birth outcomes were
also analyzed
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer generated block randomization used.
Allocation concealment (selection bias) Low risk A statistician or project member who had no direct contact with
subjects maintained allocation
Incomplete outcome data (attrition bias)
All outcomes
Low risk ITT analysis not performed.Women were excluded from analy-
sis if there were no follow-up assessments and if there were early
deliveries
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Urine toxicology used.
CBT=Cognitive behavioural therapy;MET=Motivational enhancement therapy;MI=Motivational interviewing;MMT=Methadone
maintenance therapy; OB/Gyn = Obstetrical/gynecological;
BA = brief advice therapy.
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Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Amato 2006 Inappropriate study design: a systematic review.
Ashley 2003 Inappropriate study design: review article.
Bolnick 2003 Inappropriate study design: review article.
Brady 1993 Inappropriate study design: matched case control, not randomized
Brigham 2010 Uses Winhusen 2008 data and looks at consecutive weeks attended (as proxy for retention)
Chang 1992 Inappropriate study design: not randomized.
Chang 2005 Excluded as the type of participants were not in the inclusion criteria: alcohol dependent, not illicit
drug-using
Chazotte 1995 Inappropriate study design: retrospective cohort.
Clark 2001 Inappropriate study design: not randomized; and no intervention was analysed
Daley 2005 Inappropriate study design: not a RCT; and because there was no intervention studies. This article
concerned the development of a Quality of Life index
Day 2003 Inappropriate study design: retrospective case review.
Drozdick 2002 Excluded as the intervention was not within the scope of the review: comparison of methadone trough
levels between symptomatic and asymptomatic women
Egelko 1998 Inappropriate study design: cohort study with non-perinatal controls
Elk 1995 Inappropriate study design: cohort study.
Elk 1997 Inappropriate study design: cohort study.
Erickson 2008 Uses Winhusen 2008 data and looks at impact of therapist on abstinence.
Finnegan 2005 Inappropriate study design: review article.
Fischer 1999 Excluded as the intervention was not in scope of the review: pharmacological intervention
Funai 2003 Inappropriate study design: retrospective cohort.
Fundaro 2004 Excluded as the study design and participants were not in the scope of the review: cohort study with
comparison group and the participants were infants with perinatal illicit drug exposure
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(Continued)
Greenfield 2011 Excluded as the study design and intervention were not in the scope of the review: review article
Hodnett 2010 Excluded as the study design and intervention were not in the scope of the review: Cochrane review
Hulse 2002 Excluded as the study design and intervention were not in the scope of the review: case series evaluating
a pharmacological intervention
Jansson 2003 Inappropriate study design: retrospective case series.
Jones 2002 Inappropriate study design: cohort study.
Jones 2004 Inappropriate study design: cohort study.
Jones 2011a Excluded as the study participants were not in the scope of the review: targets male partners of pregnant
women
Kastner 2002 Inappropriate study design: cohort study.
Kropp 2010 Uses Winhusen 2008 data with birth outcomes, but does not stratify.
Kukko 1999 Inappropriate study design: case series.
Nishimoto 2001 Excluded as the study participants and intervention were not in the scope of the review: postpartum
patients and no psychosocial intervention
Ondersma 2005 Excluded as the study participants were not in the scope of the review: postpartum
Ondersma 2007 Excluded as the study participants were not in the scope of the review: targeted postpartum women
Ondersma 2009 Uses Winhusen 2008 and looks at impact of baseline motivation on abstinence.
Rayburn 2004 Inappropriate study design: review article.
Roy 2011 Inappropriate study design.
Schottenfeld 2011 Excluded as no data related to pregnant women was specifically referenced and data could not be
stratified
Seracini 1996 Inappropriate study design: cohort study.
Shieh 2002 Inappropriate study design: cohort study.
Svikis 1998 Inappropriate study design: cohort study.
Sweeney 2000 Inappropriate study design: cohort study.
Tuten 2006 Excluded as citation was only for oral session.
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(Continued)
Tuten 2012b Analyzes cigarette smoking and treatment for cigarette use (no an illicit substance)
Unger 2011 Inappropriate study design: case series.
Weisdorf 1999 Inappropriate study design: cohort study with historical control
Wexler 1998 Inappropriate study design: case series.
Whicher 2012 Inappropriate study design: cohort study.
Winhusen 2003 Inappropriate study design: review article.
Winklbaur-Hausknost 2013 Review article comparing a pilot study and a RCT.
Wong 2011 Inappropriate study design: review article.
Yonkers 2009 Inappropriate study design: cohort study.
Zlotnick 1996 Inappropriate study design: cohort study.
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D A T A A N D A N A L Y S E S
Comparison 1. Any psychosocial intervention vs. control: neonatal outcomes
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Preterm birth (< 37 weeks
gestation)
3 264 Risk Ratio (M-H, Random, 95% CI) 0.71 [0.34, 1.51]
2 Positive neonatal toxicology at
delivery (any drug)
1 89 Risk Ratio (M-H, Random, 95% CI) 1.91 [0.86, 4.24]
3 Low birth weight (< 2500 g) 1 160 Risk Ratio (M-H, Random, 95% CI) 0.72 [0.36, 1.43]
4 Days hospitalized after delivery 2 103 Mean Difference (IV, Random, 95% CI) -1.27 [-2.52, -0.03]
Comparison 2. Any psychosocial intervention vs. control: maternal outcomes
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Positive urine drug test (end of
treatment)
3 367 Risk Ratio (M-H, Random, 95% CI) 1.14 [0.75, 1.73]
2 Positive urine at 1 month+ 1 159 Risk Ratio (M-H, Random, 95% CI) 1.13 [0.55, 2.31]
3 Positive urine at delivery 2 217 Risk Ratio (M-H, Random, 95% CI) 1.18 [0.52, 2.65]
4 Retention at treatment
completion
9 743 Risk Ratio (M-H, Random, 95% CI) 0.99 [0.93, 1.06]
5 Short term treatment retention 6 514 Risk Ratio (M-H, Random, 95% CI) 1.00 [0.90, 1.10]
6 Retention in treatment at
delivery
1 89 Risk Ratio (M-H, Random, 95% CI) 0.97 [0.50, 1.88]
Comparison 3. CM vs. control: maternal outcomes
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Positive urine drug test (end of
treatment)
1 89 Risk Ratio (M-H, Random, 95% CI) 1.91 [0.86, 4.24]
2 Positive urine at delivery 1 89 Risk Ratio (M-H, Random, 95% CI) 1.91 [0.86, 4.24]
3 Retention at treatment
completion
6 388 Risk Ratio (M-H, Random, 95% CI) 1.03 [0.92, 1.16]
4 Short term treatment retention 2 88 Risk Ratio (M-H, Random, 95% CI) 1.10 [0.70, 1.73]
5 Retention at delivery 1 89 Risk Ratio (M-H, Random, 95% CI) 0.97 [0.50, 1.88]
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Comparison 4. MIB vs. control: maternal outcomes
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Positive urine drug test (end of
treatment)
2 278 Risk Ratio (M-H, Random, 95% CI) 0.96 [0.63, 1.48]
2 Positive urine drug test at three
months (follow-up)
1 159 Risk Ratio (M-H, Random, 95% CI) 1.13 [0.55, 2.31]
3 Positive urine at delivery 1 128 Risk Ratio (M-H, Random, 95% CI) 0.84 [0.57, 1.24]
4 Retention at treatment
completion
3 355 Risk Ratio (M-H, Random, 95% CI) 0.97 [0.89, 1.06]
5 Short term treatment retention 3 334 Risk Ratio (M-H, Random, 95% CI) 0.99 [0.88, 1.12]
Analysis 1.1. Comparison 1 Any psychosocial intervention vs. control: neonatal outcomes, Outcome 1
Preterm birth (< 37 weeks gestation).
Review: Psychosocial interventions for pregnant women in outpatient illicit drug treatment programs compared to other interventions
Comparison: 1 Any psychosocial intervention vs. control: neonatal outcomes
Outcome: 1 Preterm birth (< 37 weeks gestation)
Study or subgroup
Psychosocial
intervention Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Elk 1998 0/6 2/6 6.4 % 0.20 [ 0.01, 3.46 ]
Jones 2011 14/47 11/42 49.9 % 1.14 [ 0.58, 2.23 ]
Yonkers 2012 8/79 17/84 43.7 % 0.50 [ 0.23, 1.09 ]
Total (95% CI) 132 132 100.0 % 0.71 [ 0.34, 1.51 ]
Total events: 22 (Psychosocial intervention), 30 (Control)
Heterogeneity: Tau2 = 0.18; Chi2 = 3.40, df = 2 (P = 0.18); I2 =41%
Test for overall effect: Z = 0.89 (P = 0.37)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours psychosocial(any) Favours usual care
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Analysis 1.2. Comparison 1 Any psychosocial intervention vs. control: neonatal outcomes, Outcome 2
Positive neonatal toxicology at delivery (any drug).
Review: Psychosocial interventions for pregnant women in outpatient illicit drug treatment programs compared to other interventions
Comparison: 1 Any psychosocial intervention vs. control: neonatal outcomes
Outcome: 2 Positive neonatal toxicology at delivery (any drug)
Study or subgroup
Psychosocial
intervention Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Jones 2011 15/47 7/42 100.0 % 1.91 [ 0.86, 4.24 ]
Total (95% CI) 47 42 100.0 % 1.91 [ 0.86, 4.24 ]
Total events: 15 (Psychosocial intervention), 7 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.60 (P = 0.11)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours psychosocial(any) Favours control
Analysis 1.3. Comparison 1 Any psychosocial intervention vs. control: neonatal outcomes, Outcome 3 Low
birth weight (< 2500 g).
Review: Psychosocial interventions for pregnant women in outpatient illicit drug treatment programs compared to other interventions
Comparison: 1 Any psychosocial intervention vs. control: neonatal outcomes
Outcome: 3 Low birth weight (< 2500 g)
Study or subgroup
Psychosocial
intervention Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Yonkers 2012 11/76 17/84 100.0 % 0.72 [ 0.36, 1.43 ]
Total (95% CI) 76 84 100.0 % 0.72 [ 0.36, 1.43 ]
Total events: 11 (Psychosocial intervention), 17 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.95 (P = 0.34)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours psychosocial(any) Favours control
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Analysis 1.4. Comparison 1 Any psychosocial intervention vs. control: neonatal outcomes, Outcome 4 Days
hospitalized after delivery.
Review: Psychosocial interventions for pregnant women in outpatient illicit drug treatment programs compared to other interventions
Comparison: 1 Any psychosocial intervention vs. control: neonatal outcomes
Outcome: 4 Days hospitalized after delivery
Study or subgroup
Psychosocial
intervention Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Carroll 1995 7 41.3 (15) 7 38.1 (16.7) 0.6 % 3.20 [ -13.43, 19.83 ]
Jones 2011 47 2.9 (2.3995) 42 4.2 (3.4348) 99.4 % -1.30 [ -2.54, -0.06 ]
Total (95% CI) 54 49 100.0 % -1.27 [ -2.52, -0.03 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.28, df = 1 (P = 0.60); I2 =0.0%
Test for overall effect: Z = 2.01 (P = 0.044)
Test for subgroup differences: Not applicable
-100 -50 0 50 100
Favours psychosocial(any) Favours control
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Analysis 2.1. Comparison 2 Any psychosocial intervention vs. control: maternal outcomes, Outcome 1
Positive urine drug test (end of treatment).
Review: Psychosocial interventions for pregnant women in outpatient illicit drug treatment programs compared to other interventions
Comparison: 2 Any psychosocial intervention vs. control: maternal outcomes
Outcome: 1 Positive urine drug test (end of treatment)
Study or subgroup Any Pyschosocial Int. Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Jones 2011 15/47 7/42 24.5 % 1.91 [ 0.86, 4.24 ]
Winhusen 2008 22/85 24/87 54.8 % 0.94 [ 0.57, 1.54 ]
Yonkers 2012 9/55 8/51 20.7 % 1.04 [ 0.44, 2.50 ]
Total (95% CI) 187 180 100.0 % 1.14 [ 0.75, 1.73 ]
Total events: 46 (Any Pyschosocial Int.), 39 (Control)
Heterogeneity: Tau2 = 0.02; Chi2 = 2.27, df = 2 (P = 0.32); I2 =12%
Test for overall effect: Z = 0.63 (P = 0.53)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours psychosocial(any) Favours control
45Psychosocial interventions for pregnant women in outpatient illicit drug treatment programs compared to other interventions (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 2.2. Comparison 2 Any psychosocial intervention vs. control: maternal outcomes, Outcome 2
Positive urine at 1 month+.
Review: Psychosocial interventions for pregnant women in outpatient illicit drug treatment programs compared to other interventions
Comparison: 2 Any psychosocial intervention vs. control: maternal outcomes
Outcome: 2 Positive urine at 1 month+
Study or subgroup Any PSI Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Winhusen 2008 13/78 12/81 100.0 % 1.13 [ 0.55, 2.31 ]
Total (95% CI) 78 81 100.0 % 1.13 [ 0.55, 2.31 ]
Total events: 13 (Any PSI), 12 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.32 (P = 0.75)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours psychosocial(any) Favours control
Analysis 2.3. Comparison 2 Any psychosocial intervention vs. control: maternal outcomes, Outcome 3
Positive urine at delivery.
Review: Psychosocial interventions for pregnant women in outpatient illicit drug treatment programs compared to other interventions
Comparison: 2 Any psychosocial intervention vs. control: maternal outcomes
Outcome: 3 Positive urine at delivery
Study or subgroup Any PSI Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Jones 2011 15/47 7/42 41.1 % 1.91 [ 0.86, 4.24 ]
Yonkers 2012 26/64 31/64 58.9 % 0.84 [ 0.57, 1.24 ]
Total (95% CI) 111 106 100.0 % 1.18 [ 0.52, 2.65 ]
Total events: 41 (Any PSI), 38 (Control)
Heterogeneity: Tau2 = 0.25; Chi2 = 3.46, df = 1 (P = 0.06); I2 =71%
Test for overall effect: Z = 0.40 (P = 0.69)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours psychosocial(any) Favours control
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Analysis 2.4. Comparison 2 Any psychosocial intervention vs. control: maternal outcomes, Outcome 4
Retention at treatment completion.
Review: Psychosocial interventions for pregnant women in outpatient illicit drug treatment programs compared to other interventions
Comparison: 2 Any psychosocial intervention vs. control: maternal outcomes
Outcome: 4 Retention at treatment completion
Study or subgroup Experimental Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Elk 1998 5/6 4/6 1.0 % 1.25 [ 0.64, 2.44 ]
Haug 2004 26/30 28/33 11.1 % 1.02 [ 0.84, 1.25 ]
Jones 2001 41/44 34/36 35.6 % 0.99 [ 0.88, 1.10 ]
Jones 2011 13/47 12/42 1.0 % 0.97 [ 0.50, 1.88 ]
O’Neill 1996 40/47 40/45 18.0 % 0.96 [ 0.82, 1.12 ]
Silverman 2001 11/20 8/20 1.0 % 1.38 [ 0.71, 2.68 ]
Svikis 1997 27/40 18/36 2.9 % 1.35 [ 0.91, 2.00 ]
Svikis 2007 31/50 25/41 4.2 % 1.02 [ 0.73, 1.41 ]
Winhusen 2008 81/102 81/98 25.0 % 0.96 [ 0.84, 1.10 ]
Total (95% CI) 386 357 100.0 % 0.99 [ 0.93, 1.06 ]
Total events: 275 (Experimental), 250 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 4.94, df = 8 (P = 0.76); I2 =0.0%
Test for overall effect: Z = 0.16 (P = 0.87)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours psychosocial(any) Favours control
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Analysis 2.5. Comparison 2 Any psychosocial intervention vs. control: maternal outcomes, Outcome 5
Short term treatment retention.
Review: Psychosocial interventions for pregnant women in outpatient illicit drug treatment programs compared to other interventions
Comparison: 2 Any psychosocial intervention vs. control: maternal outcomes
Outcome: 5 Short term treatment retention
Study or subgroup Any psychosocial Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Elk 1998 6/6 6/6 11.3 % 1.00 [ 0.75, 1.34 ]
Haug 2004 26/30 28/33 23.6 % 1.02 [ 0.84, 1.25 ]
Mullins 2004 16/35 15/36 3.4 % 1.10 [ 0.65, 1.86 ]
O’Neill 1996 37/47 36/45 22.0 % 0.98 [ 0.80, 1.21 ]
Svikis 1997 15/40 10/36 2.2 % 1.35 [ 0.70, 2.62 ]
Winhusen 2008 75/102 75/98 37.4 % 0.96 [ 0.82, 1.13 ]
Total (95% CI) 260 254 100.0 % 1.00 [ 0.90, 1.10 ]
Total events: 175 (Any psychosocial), 170 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.31, df = 5 (P = 0.93); I2 =0.0%
Test for overall effect: Z = 0.08 (P = 0.94)
Test for subgroup differences: Not applicable
0.1 0.2 0.5 1 2 5 10
Favours psychosocial(any) Favours control
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Analysis 2.6. Comparison 2 Any psychosocial intervention vs. control: maternal outcomes, Outcome 6
Retention in treatment at delivery.
Review: Psychosocial interventions for pregnant women in outpatient illicit drug treatment programs compared to other interventions
Comparison: 2 Any psychosocial intervention vs. control: maternal outcomes
Outcome: 6 Retention in treatment at delivery
Study or subgroup Any PSI Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Jones 2011 13/47 12/42 100.0 % 0.97 [ 0.50, 1.88 ]
Total (95% CI) 47 42 100.0 % 0.97 [ 0.50, 1.88 ]
Total events: 13 (Any PSI), 12 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.10 (P = 0.92)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours psychosocial(any) Favours control
Analysis 3.1. Comparison 3 CM vs. control: maternal outcomes, Outcome 1 Positive urine drug test (end of
treatment).
Review: Psychosocial interventions for pregnant women in outpatient illicit drug treatment programs compared to other interventions
Comparison: 3 CM vs. control: maternal outcomes
Outcome: 1 Positive urine drug test (end of treatment)
Study or subgroup Contingency Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Jones 2011 15/47 7/42 100.0 % 1.91 [ 0.86, 4.24 ]
Total (95% CI) 47 42 100.0 % 1.91 [ 0.86, 4.24 ]
Total events: 15 (Contingency), 7 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.60 (P = 0.11)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours CM Favours control
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Analysis 3.2. Comparison 3 CM vs. control: maternal outcomes, Outcome 2 Positive urine at delivery.
Review: Psychosocial interventions for pregnant women in outpatient illicit drug treatment programs compared to other interventions
Comparison: 3 CM vs. control: maternal outcomes
Outcome: 2 Positive urine at delivery
Study or subgroup
Contingency
Management Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Jones 2011 15/47 7/42 100.0 % 1.91 [ 0.86, 4.24 ]
Total (95% CI) 47 42 100.0 % 1.91 [ 0.86, 4.24 ]
Total events: 15 (Contingency Management), 7 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.60 (P = 0.11)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours CM Favours control
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Analysis 3.3. Comparison 3 CM vs. control: maternal outcomes, Outcome 3 Retention at treatment
completion.
Review: Psychosocial interventions for pregnant women in outpatient illicit drug treatment programs compared to other interventions
Comparison: 3 CM vs. control: maternal outcomes
Outcome: 3 Retention at treatment completion
Study or subgroup CM Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Elk 1998 5/6 4/6 3.0 % 1.25 [ 0.64, 2.44 ]
Jones 2001 41/44 34/36 70.2 % 0.99 [ 0.88, 1.10 ]
Jones 2011 13/47 12/42 3.1 % 0.97 [ 0.50, 1.88 ]
Silverman 2001 11/20 8/20 3.0 % 1.38 [ 0.71, 2.68 ]
Svikis 1997 27/40 18/36 8.6 % 1.35 [ 0.91, 2.00 ]
Svikis 2007 31/50 25/41 12.1 % 1.02 [ 0.73, 1.41 ]
Total (95% CI) 207 181 100.0 % 1.03 [ 0.92, 1.16 ]
Total events: 128 (CM), 101 (Control)
Heterogeneity: Tau2 = 0.00; Chi2 = 5.27, df = 5 (P = 0.38); I2 =5%
Test for overall effect: Z = 0.56 (P = 0.57)
Test for subgroup differences: Not applicable
0.1 0.2 0.5 1 2 5 10
Favours CM Favours control
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Analysis 3.4. Comparison 3 CM vs. control: maternal outcomes, Outcome 4 Short term treatment
retention.
Review: Psychosocial interventions for pregnant women in outpatient illicit drug treatment programs compared to other interventions
Comparison: 3 CM vs. control: maternal outcomes
Outcome: 4 Short term treatment retention
Study or subgroup
Contingency
management Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Elk 1998 6/6 6/6 68.4 % 1.00 [ 0.75, 1.34 ]
Svikis 1997 15/40 10/36 31.6 % 1.35 [ 0.70, 2.62 ]
Total (95% CI) 46 42 100.0 % 1.10 [ 0.70, 1.73 ]
Total events: 21 (Contingency management), 16 (Control)
Heterogeneity: Tau2 = 0.06; Chi2 = 1.84, df = 1 (P = 0.17); I2 =46%
Test for overall effect: Z = 0.41 (P = 0.68)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours CM Favours control
Analysis 3.5. Comparison 3 CM vs. control: maternal outcomes, Outcome 5 Retention at delivery.
Review: Psychosocial interventions for pregnant women in outpatient illicit drug treatment programs compared to other interventions
Comparison: 3 CM vs. control: maternal outcomes
Outcome: 5 Retention at delivery
Study or subgroup
Contingency
Management Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Jones 2011 13/47 12/42 100.0 % 0.97 [ 0.50, 1.88 ]
Total (95% CI) 47 42 100.0 % 0.97 [ 0.50, 1.88 ]
Total events: 13 (Contingency Management), 12 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.10 (P = 0.92)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours CM Favours control
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Analysis 4.1. Comparison 4 MIB vs. control: maternal outcomes, Outcome 1 Positive urine drug test (end
of treatment).
Review: Psychosocial interventions for pregnant women in outpatient illicit drug treatment programs compared to other interventions
Comparison: 4 MIB vs. control: maternal outcomes
Outcome: 1 Positive urine drug test (end of treatment)
Study or subgroup Favours MIB Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Winhusen 2008 22/85 24/87 75.6 % 0.94 [ 0.57, 1.54 ]
Yonkers 2012 9/55 8/51 24.4 % 1.04 [ 0.44, 2.50 ]
Total (95% CI) 140 138 100.0 % 0.96 [ 0.63, 1.48 ]
Total events: 31 (Favours MIB), 32 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.04, df = 1 (P = 0.84); I2 =0.0%
Test for overall effect: Z = 0.17 (P = 0.86)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours MIB Favours control
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Analysis 4.2. Comparison 4 MIB vs. control: maternal outcomes, Outcome 2 Positive urine drug test at
three months (follow-up).
Review: Psychosocial interventions for pregnant women in outpatient illicit drug treatment programs compared to other interventions
Comparison: 4 MIB vs. control: maternal outcomes
Outcome: 2 Positive urine drug test at three months (follow-up)
Study or subgroup MIB Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Winhusen 2008 13/78 12/81 100.0 % 1.13 [ 0.55, 2.31 ]
Total (95% CI) 78 81 100.0 % 1.13 [ 0.55, 2.31 ]
Total events: 13 (MIB), 12 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.32 (P = 0.75)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours MIB Favours control
Analysis 4.3. Comparison 4 MIB vs. control: maternal outcomes, Outcome 3 Positive urine at delivery.
Review: Psychosocial interventions for pregnant women in outpatient illicit drug treatment programs compared to other interventions
Comparison: 4 MIB vs. control: maternal outcomes
Outcome: 3 Positive urine at delivery
Study or subgroup MIB Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Yonkers 2012 26/64 31/64 100.0 % 0.84 [ 0.57, 1.24 ]
Total (95% CI) 64 64 100.0 % 0.84 [ 0.57, 1.24 ]
Total events: 26 (MIB), 31 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.89 (P = 0.38)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours MIB Favours control
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Analysis 4.4. Comparison 4 MIB vs. control: maternal outcomes, Outcome 4 Retention at treatment
completion.
Review: Psychosocial interventions for pregnant women in outpatient illicit drug treatment programs compared to other interventions
Comparison: 4 MIB vs. control: maternal outcomes
Outcome: 4 Retention at treatment completion
Study or subgroup MIB Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Haug 2004 26/30 28/33 20.5 % 1.02 [ 0.84, 1.25 ]
O’Neill 1996 40/47 40/45 33.3 % 0.96 [ 0.82, 1.12 ]
Winhusen 2008 81/102 81/98 46.2 % 0.96 [ 0.84, 1.10 ]
Total (95% CI) 179 176 100.0 % 0.97 [ 0.89, 1.06 ]
Total events: 147 (MIB), 149 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.30, df = 2 (P = 0.86); I2 =0.0%
Test for overall effect: Z = 0.61 (P = 0.54)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours MIB Favours control
55Psychosocial interventions for pregnant women in outpatient illicit drug treatment programs compared to other interventions (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 4.5. Comparison 4 MIB vs. control: maternal outcomes, Outcome 5 Short term treatment
retention.
Review: Psychosocial interventions for pregnant women in outpatient illicit drug treatment programs compared to other interventions
Comparison: 4 MIB vs. control: maternal outcomes
Outcome: 5 Short term treatment retention
Study or subgroup MIB Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Haug 2004 26/30 28/33 36.7 % 1.02 [ 0.84, 1.25 ]
Mullins 2004 16/35 15/36 5.3 % 1.10 [ 0.65, 1.86 ]
Winhusen 2008 75/102 75/98 58.0 % 0.96 [ 0.82, 1.13 ]
Total (95% CI) 167 167 100.0 % 0.99 [ 0.88, 1.12 ]
Total events: 117 (MIB), 118 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.37, df = 2 (P = 0.83); I2 =0.0%
Test for overall effect: Z = 0.17 (P = 0.87)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours MIB Favours control
A P P E N D I C E S
Appendix 1. Search strategy
For the original search executed in May 2006, we searched the Cochrane Drugs and Alcohol Group Register (May 2006); CENTEAL,
(The Cochrane Library, Issue 3, 2005); MEDLINE (1996 to August 2006); EMBASE (January 1996 to August 2006); and CINAHL
(January 1982 to August 2006). We followed the ’optimal’MEDLINE and EMBASE sensitive search strategies devised by theCochrane
Collaboration for RCTs as published in Section 6.4 of the Cochrane Handbook for Systematic Reviews of Interventions (Higgins 2011) in
order to identify studies relevant to this Cochrane review.
Search strategy to locate drug abuse
1. SUBSTANCE ADJ RELATED ADJ DISORDERS
2. SUBSTANCE-RELATED-DISORDERS#.DE.
3. ADDICT$4.TI,AB.
4. (OVERDOS$2 OR OVER-DOS$2).TI,AB.
5. INTOXICAT$3.TI,AB.
6. (ABSTINEN$2 OR ABSTAIN$2).TI,AB.
7. WITHDRAW$2.TI,AB.
8. (ABUSE$2 OR USE).TI,AB.
9. (EXCESSIVE$2 ADJ USE$1).TI,AB.
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10. (USE$2 ADJ DISORDER$2).TI,AB.
11. PSYCHOSES-SUBSTANCE-INDUCED
12. PSYCHOSES-SUBSTANCE-INDUCED#.DE.
13. 1 OR 2 OR 3 OR 4 OR 5 OR 6 OR 7 OR 8 OR 9 OR 10 OR 11 OR 12
Search strategy to identify drugs
14.HEROIN or HEROIN#.W..DE. or HEROIN.TI,AB.
15.NARCOTICS or NARCOTICS#.W..DE.
16.OPIOID.TI,AB. Or OPIATE.TI,AB. Or OPIATE.RN.
17.ANTI-ANXIETY-AGENTS#.DE.
18.BENZODIAZEPINE or BENZODIAZEPINES#.W..DE.
19.BARBITURATES or BARBITURATES#.W..DE. or BARBITURATES.TI,AB.
20.AMPHETAMINES or AMPHETAMINE#.W..DE. or AMPHETAMINE.TI,AB.
21.DESIGNER ADJ DRUGS or DESIGNER-DRUGS#.DE. or (DESIGNER ADJ DRUGS).TI,AB. or (DESIGNER ADJ
DRUGS).RN.
22.HALLUCINOGENS or HALLUCINOGENS#.W..DE. or HALLUCINOGENS.TI,AB. or HALLUCINOGENS.RN.
23.STREET ADJ DRUGS or STREET-DRUGS#.DE. or(STREET ADJ DRUGS).TI,AB. or STREET-DRUGS.TI,AB.
24.COCAINE or COCAINE#.W..DE. or COCAINE.TI,AB. or COCAINE.RN.
25.ALOCHOLS or ALCOHOLS#.W..DE. or ALCOHOL.TI,AB.
26.LYSERGIC ADJ ACID or LYSERGIC-ACID#.DE. or (LYSERGIC ADJ ACID).TI,AB. or (LYSERGIC ADJ ACID).RN. or
LSD.TI,AB. or LSD.RN. or LSD or LYSERGIC-ACID-DIETHYLAMIDE#.DE.
27.KETAMINE or KETAMINE#.W..DE. or KETAMINE.TI,AB. or KETAMINE.RN.
28.CANNABIS or CANNABIS#.W..DE. or CANNABIS.TI,AB. or CANNABIS.RN.
29.MARIHUANA.TI,AB. or MARIHUANA.RN. or MARIJUANA orMARIJUANA-SMOKING#.DE. or MARIJUANA-ABUSE#
.DE. or MARIJUANA.TI,AB.
30.HASHISH or HASHISH.TI,AB.
31.OPIUM or OPIUM#.W..DE. or OPIUM.TI,AB.
32.INHALANT$2.TI,AB. or (INHALANT$2 ADJ ABUSE$2).TI,AB.
33.SOLVENT or SOLVENTS#.W..DE. or SOLVENT$2.TI,AB. or SOLVENT$2.RN.
34.(STEROID$2 ADJ ABUSE).TI,AB. or ANABOLIC ADJ STEROIDS or ANABOLIC-AGENTS#.DE.
35.(ANABOLIC ADJ AGENT$2).TI,AB. AND PERFORM$6.TI,AB.
36.METHADONE or METHADONE#.W..DE. or METHADONE.TI,AB. METHADONE.RN.
37.14 OR 15 OR 16 OR 17 OR 18 OR 19 OR 20 OR 21 OR 22 OR 23 OR 24 OR 25 OR 26 OR 27 OR 28 OR 29 OR 30 OR
31 OR 32 OR 33 OR 34 OR 35 OR 36
Search strategy to locate interventions
38.PATIENT ADJ COMPLIANCE or PATIENT-COMPLIANCE#.DE.
39.(ATTENDANCE ADJ INCENTIVE$2).TI,AB.
40.INCENTIVE$2.TI,AB. or VOUCHER$2.TI,AB.
41.PSYCHOTHERAPY or PSYCHOTHERAPY#.W..DE.
42.BEHAVIOR-THERAPY#.DE. or BEHAVIOR ADJ THERAPY
43.REINFORCEMENT ADJ PSYCHOLOGY or REINFORCEMENT-PSYCHOLOGY#.DE. or REINFORCEMENT.TI,AB.
44.MOTIVATION or MOTIVATION#.W..DE. or MOTIVATION ADJ INTERVIEWING
45.(CONTINGENCY ADJ MANAGEMENT).TI,AB.
46.38 OR 39 OR 40 OR 41 OR 42 OR 43 OR 44 OR 45
Search strategy to identify pregnancy
47.PREGNANCY or PREGNANCY#.W..DE. or PREGNAN$4.TI,AB.
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Search strategy to locate RCTs and different types of studies
48.PT=RANDOMIZED-CONTROLLED-TRIAL or RANDOMIZED ADJ CONTROLLED ADJ TRIAL or RANDOMIZED-
CONTROLLED-TRIALS#.DE.
49.PT=CONTROLLED-CLINICAL-TRIAL or RANDOM ADJ ALLOCATION or RANDOM-ALLOCATION.DE.
50.DOUBLE ADJ BLIND ADJ METHOD or DOUBLE-BLIND-METHOD.DE.
51.SINGLE-BLIND-METHOD.DE.
52.PT=CLINICAL-TRIAL$ or CLINICAL ADJ TRIALS or CLINICAL-TRIALS#.DE. or (CLINIC$2 ADJ TRIAL$2).TI,AB.
53.((SINGL$2 OR DOUBL$2 OR TREBL$2 OR TRIPL$2) ADJ (BLIND$2 ORMASK$2)).TI,AB.
54.PLACEBOS or PLACEBOS#.W..DE. or PLACEBO$2.TI,AB.
55.RANDOM$4.TI,AB.
56.RESEARCH ADJ DESIGN or RESEARCH-DESIGN#.DE.
57.COMPARATIVE ADJ STUDY or COMPARATIVE-STUDY.DE.
58.EVALUATION-STUDIES#.DE.
59.PROSPECTIVE-STUDIES#.DE.
60.48 OR 49 OR 51 OR 52 OR 53 OR 54 OR 55 OR 57 OR 59
Search strategy to locate studies for this review
61.13 and 37 and 46 and 47 and 60
Appendix 2. CENTRAL search strategy
1. MeSH descriptor Substance-Related Disorders explode all trees
2. ((stimulant* or polydrug* or drug* or substance) near (abstain* or abstinen* or abus* or addict* or dependen* or disorder* or
intoxicat* or misuse* or over dos* or overdos* or withdraw*)):ab,ti
3. (#1 OR #2)
4. (abstain* or abstinen* or abus* or addict* or drug user* or dependen* or inject* drug* or intoxicat* or misus* or overdos* or
illicit use* or withdraw*):ti,ab,kw
5. MeSH descriptor Heroin explode all trees
6. (heroin or morphine* or diamorphine or diacetylmorphine or morfin* or narcotic* or methadone):ti,ab,kw
7. MeSH descriptor Methadone explode all trees
8. (opioid* or opiate* or opium):ti,ab,kw
9. MeSH descriptor Narcotics explode all trees
10. MeSH descriptor Anti-Anxiety Agents explode all trees
11. MeSH descriptor Benzodiazepines explode all trees
12. (benzodiazepine):ti,ab,kw
13. MeSH descriptor Barbiturates explode all trees
14. (barbiturates):ti,ab,kw
15. MeSH descriptor Amphetamine explode all trees
16. (amphetamine* or methamphetamine*):ti,ab,kw
17. (Designer near/2 Drug*):ti,ab,kw
18. MeSH descriptor Hallucinogens explode all trees
19. (ecstasy or MDMA or hallucinogen*):ti,ab,kw
20. MeSH descriptor Street Drugs explode all trees
21. MeSH descriptor Cocaine explode all trees
22. (crack or cocaine):ti,ab,kw
23. (alcohol*):ti,ab,kw
24. MeSH descriptor Lysergic Acid explode all trees
25. (Lysergic NEXT Acid):ti,ab,kw
26. (LSD):ti,ab,kw
27. (ketamine):ti,ab,kw
28. MeSH descriptor Ketamine explode all trees
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29. MeSH descriptor Cannabis explode all trees
30. (cannabis or marijuana or marihuana or hashish):ti,ab,kw
31. (Inhalant NEXT abuse ):ti,ab,kw
32. (Solvent*):ti,ab,kw
33. MeSH descriptor Solvents explode all trees
34. (anabolic near steroid*):ti,ab,kw
35. MeSH descriptor Anabolic Agents explode all trees
36. (steroid* near/3 abuse):ti,ab
37. (anabolic near agent*):ti,ab
38. (#5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12 OR #13 OR #14 OR #15 OR #16 OR #17 OR #18 OR #19 OR
#20 OR #21 OR #22 OR #23 OR #24 OR #25 OR #26 OR #27 OR #28 OR #29 OR #30 OR #31 OR #32 OR #33 OR #34 OR
#35 OR #36 OR #37)
39. (#4 AND #38)
40. (#3 OR #39)
41. MeSH descriptor Patient Compliance explode all trees
42. (patient NEXT compliance):ti,ab,kw
43. MeSH descriptor Psychotherapy explode all trees
44. MeSH descriptor Reinforcement (Psychology) explode all trees
45. MeSH descriptor Motivation explode all trees
46. (behavi* near/3 therap*):ti,ab
47. (psychotherap* or psychosocial or voucher* or incentive* or reinforcement or motivation*):ti,ab,kw
48. (contingency near management):ti,ab,kw
49. (#41 OR #42 OR #43 OR #44 OR #45 OR #46 OR #47 OR #48)
50. MeSH descriptor Pregnancy explode all trees
51. (pregnan*):ti,ab,kw
52. (#50 OR #51)
53. (#40 AND #49 AND #52)
Appendix 3. PubMed search strategy
1. Substance-related disorders[MeSH]
2. Psychoses, Substance-Induced[MeSH]
3. (abstain*[tiab] OR abstinen*[tiab] OR abus*[tiab] OR addict*[tiab] OR dependen*[tiab] OR disorder*[tiab] OR
intoxicat*[tiab] OR misuse*[tiab] OR use*[tiab] OR over-dos*[tiab] OR overdos*[tiab] OR withdraw*[tiab])
4. #1 OR #2 OR #3
5. Heroin [MH]
6. Anti-anxiety agents [MeSH]
7. Benzodiazepines [MeSH]
8. Barbiturates [MeSH]
9. Amphetamines [MeSH]
10. Designer drugs [MeSH]
11. “designer drug”[tiab]
12. “illicit drug”[tiab]
13. Antidepressive agents [MeSH]
14. Hallucinogens [MeSH]
15. Street drugs [MeSH] OR street-drug* [tiab]
16. Cocaine [MeSH]
17. Lysergic acid [MeSH] or lysergic-acid* [tiab] or LSD[tiab]
18. Ketamine [MeSH]
19. Cannabis [MeSH]
20. Opium [MeSH]
21. “steroid abuse”[tiab]
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22. Anabolic steroids [MeSH]
23. drug*[tiab] OR substance[tiab] OR polidrug*[tiab] OR alcohol*[tiab] OR amphetamine*[tiab] OR cannabis[tiab] OR
marihuana[tiab] or marijuana[tiab] OR “hash oil*”[tiab] OR hashish[tiab] OR cocaine[tiab] OR hallucinogen* [tiab] OR
heroin[tiab] OR mdma[tiab] OR ecstasy[tiab] OR methamphetamine*[tiab] OR narcotic* [tiab] OR ketamine[tiab] OR
opioid*[tiab] OR opiate* [tiab] OR opium[tiab] OR tranquilizer*[tiab] OR tranquiliser*[tiab] OR inhalant*[tiab] OR
barbiturate*[tiab] OR solvent*[tiab] OR stimulant*[tiab]
24. #5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12 OR #13 OR #14 OR #16 OR #17 OR #18 OR #19 OR #20 OR #
21 OR #22
25. Patient Compliance[MH]
26. Psychotherapy[MH]
27. reinforcement psychology[MeSH Terms]
28. motivation[mh]
29. (behavi*[tiab] AND therap*[tiab])
30. (psychotherap*[tiab] OR psychosocial[tiab] OR voucher*[tiab] OR incentive*[tiab] OR reinforcement[tiab] OR
motivation*[tiab])
31. (contingency[tiab] AND management[tiab])
32. #25 OR #26 OR #27 OR #28 OR #29 OR #30 OR #31
33. “pregnancy”[MeSH Terms]
34. pregnan*[tiab]
35. #33 OR #34
36. randomized controlled trial [pt]
37. controlled clinical trial [pt]
38. randomized [tiab]
39. placebo [tiab]
40. drug therapy [sh]
41. randomly [tiab]
42. trial [tiab]
43. groups [tiab]
44. #36 OR #37 OR #38 OR #39 OR #40 OR #41 OR #42 OR #43
45. animals [mh] NOT humans [mh]
46. #44 NOT #45
47. #4 AND #24 AND #32 AND #35 AND #46
Appendix 4. EMBASE search strategy
1. ’addiction’/exp
2. dependen*:ab,ti OR addict*:ab,ti OR overdos*:ab,ti OR intoxicat*:ab,ti OR abstin*:ab,ti OR abstain:ab,ti OR withdraw*:ab,ti
OR abus*:ab,ti OR use*:ab,ti OR misus*:ab,ti OR disorder*:ab,ti
3. #1 OR #2
4. ’diamorphine’/exp
5. diamorphine:ab,ti OR heroin:ab,ti OR narcotic*:ab,ti OR drug*:ab,ti OR polydrug:ab,ti OR substance:ab,ti OR opioid:ab,ti
OR opiate:ab,ti OR opium:ab,ti OR hallucinogen*:ab,ti OR amphetamine*:ab,ti OR barbiturate:ab,ti OR inhalant*:ab,ti OR
morphine:ab,ti OR ecstasy:ab,ti OR mdma:ab,ti
6. ’street drug’/exp
7. ’designer drug’/exp
8. ’lysergic acid’/exp OR ’lysergic acid’:ab,ti OR lsd:ab,ti
9. ’cocaine’/exp OR cocaine:ab,ti
10. ’alcohol’/exp OR alcohol:ab,ti
11. ’ketamine’/exp OR ketamine:ab,ti
12. ’cannabis’/exp OR cannabis:ab,ti OR hashish:ab,ti OR marihuana:ab,ti OR marijuana:ab,ti
13. ’inhalant abuse’/exp OR inhalant:ab,ti
14. ’solvent’/exp OR solvent:ab,ti
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15. ’methadone’/exp OR methadone:ab,ti
16. ’anabolic agent’/exp
17. steroid*:ab,ti AND abuse:ab,ti
18. anabolic:ab,ti AND agent*:ab,ti
19. ’benzodiazepine’/exp OR benzodiazepine:ab,ti
20. ’amphetamine’/exp OR amphetamine:ab,ti
21. #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12 OR #13 OR #14 OR #15 OR #16 OR #17 OR #18 OR #
19 OR #20
22. ’patient compliance’/exp
23. ’psychotherapy’/exp
24. ’reinforcement’/exp
25. ’motivation’/exp
26. incentive*or:ab,ti OR voucher*:ab,ti OR psychotherap*:ab,ti OR psychosocial*:ab,ti OR reinforcement:ab,ti OR motivation*:
ab,ti
27. #22 OR #23 OR #24 OR #25 OR #26
28. ’pregnancy’/exp
29. pregnan*:ab,ti
30. #28 OR #29
31. ’crossover procedure’/exp OR ’double blind procedure’/exp OR ’single blind procedure’/exp OR ’controlled clinical trial’/exp OR
’clinical trial’/exp OR placebo:ab,ti OR ’double blind’:ab,ti OR ’single blind’:ab,ti OR assign*:ab,ti OR allocat*:ab,ti OR volunteer*:
ab,ti OR random*:ab,ti OR factorial*:ab,ti OR crossover:ab,ti OR (cross:ab,ti AND over:ab,ti) OR ’randomized controlled trial’/exp
32. #3 AND #21 AND #27 AND #30 AND #31
Appendix 5. CINAHL search strategy
1. (MH “Substance Use Disorders+”)
2. (MH “Psychoses, Substance-Induced+”)
3. TX(drug N3 addict*) or TX(drug N3 dependen*) or TX(drug N3 abuse*) or TX(drug N3 misus*)
4. TX(substance N3 addict*) or TX(substance N3 dependen*) or TX(substance N3 abuse*) or TX(substance N3 misus*)
5. TX(addict* OR overdos* OR intoxicat* OR abstin* OR abstain OR withdraw* OR abus* OR misus* OR disorder* OR
dependen*)
6. TX(use* N2 drug) or TX(use* N2 disorder) or TX(use* N2 illicit)
7. TX(use* N2 drug) or TX(use* N2 disorder) or TX(use* N2 illicit)
8. S1 or S2 or S3 or S4
9. S5 or S6 or S7
10. TX(polydrug or alcohol or opioid or opiate or opium or hallucinogen or cocaine or benzodiazepine* or amphetamine*or “anti-
anxiety-agents” or barbiturate* or “lysergic acid” or ketamine or cannabis or marihuana or marijuana or hashish or inhalant* or
solvent or steroid* or methadone or morphine)
11. MH “Narcotics”
12. MH “Designer Drugs”
13. (MH “Hallucinogens+”)
14. (MH “Methadone”)
15. (MH “Amphetamines+”)
16. (MH “Ketamine”)
17. S10 or S11 or S12 or S13 or S14 or S15 or S16
18. S9 and S17
19. S8 or S18
20. (MH “Patient Compliance+”)
21. (MH “Motivational Interviewing”) OR (MM “Counseling”)
22. (MH “Psychotherapy+”)
23. TI incentive* OR voucher OR psychotherap* OR psychosocial* OR reinforcement OR motivation* OR contingent* OR advice
24. AB incentive* OR voucher OR psychotherap* OR psychosocial* OR reinforcement OR motivation* OR contingent* OR advice
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25. TI (contingency N1 management) OR AB (contingency N1 management)
26. TI (behaviour* N2 therapy) OR AB (behaviour* N2 therapy)
27. (MH “Reinforcement (Psychology)+”)
28. S20 or S21 or S22 or S23 or S24 or S25 or S26 or S27
29. (MH “Pregnancy”)
30. TX pregnan*
31. S29 or S30
32. MH “Clinical Trials+”
33. PT Clinical trial
34. TI clinic* N1 trial* or AB clinic* N1 trial*
35. TI ( singl* or doubl* or trebl* or tripl* ) and TI ( blind* or mask* )
36. AB ( singl* or doubl* or trebl* or tripl* ) and AB ( blind* or mask* )
37. TI randomi?ed control* trial* or AB randomi?ed control* trial*
38. MH “Random Assignment”
39. TI random* allocat* or AB random* allocat*
40. MH “Placebos”
41. TI placebo* or AB placebo*
42. MH “Quantitative Studies”
43. S32 or S33 or S34 or S35 or S36 or S37 or S38 or S39 or S40 or S41 or S42
44. S19 and S28 and S31 and S43
WH A T ’ S N E W
Last assessed as up-to-date: 28 January 2015.
Date Event Description
2 April 2015 Amended Contact person email updated
H I S T O R Y
Protocol first published: Issue 2, 2006
Review first published: Issue 4, 2007
Date Event Description
16 February 2015 New citation required and conclusions have changed Conclusions changed.
28 January 2015 New search has been performed We updated the review to include reviewer recommen-
dations and new studies identified from the updated lit-
erature search up to January 2015
3 August 2007 New citation required and conclusions have changed Substantive amendment
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I N D E X T E R M S
Medical Subject Headings (MeSH)
∗Psychotherapy; Length of Stay; Patient Dropouts [statistics & numerical data]; Pregnancy Complications [psychology; ∗therapy];
Pregnancy Outcome; Pregnant Women [∗psychology]; Premature Birth [epidemiology]; Randomized Controlled Trials as Topic;
Reinforcement (Psychology); Substance-Related Disorders [psychology; ∗therapy]
MeSH check words
Female; Humans; Infant, Newborn; Pregnancy
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